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According to the American Cancer Society, approximately 21,410 women will receive a 
diagnosis of ovarian cancer, and 13,770 women will die from ovarian cancer in 2021. Typically, 
ovarian cancer is not diagnosed until it has reached stage III/IV in its progression. By later stages 
of disease, an ovarian cancer tumor has migrated to the peritoneum, existing either in single cell 
or spheroid form, and resulting in inflammation and buildup of ascites fluid, and metastasis of 
secondary tumors.  
Ascites fluid is comprised of many different secreted extracellular matrix (ECM) 
molecules, proteases and cytokines. The cytokine IL-6 is abundant in ascites fluid and can bind 
to its receptor, signaling the JAK/STAT3 cascade, activating STAT3 and promoting transcription 
of target genes. Constitutive activation of STAT3 has been found in the ascites fluid and ascites-
derived ovarian cancer cells of ovarian cancer patients and correlates with aggressive tumor 
growth and metastasis.  
Cisplatin is a chemotherapeutic drug that is typically used as a first-line treatment of 
ovarian cancer. Over time, ovarian cancer evolves to resist the DNA damaging effects of 
cisplatin by evading apoptosis. Another mechanism by which ovarian cancer cells develop 
chemoresistance is through the Epithelial-to-Mesenchymal Transition (EMT). Aberrant STAT3 
activity in ovarian cancer has been implicated in both evasion of apoptosis and EMT, making 
STAT3 an attractive target for understanding chemotherapy resistance in ovarian cancer.  
xiii 
 
To study STAT3 in cisplatin resistant ovarian cancer, a clinically relevant model is 
required. Chowanadasi et al. adapted an ovarian cancer cell line that closely modeled the 
heterogeneity of high grade serous ovarian cancer (OVCAR-8) to resist cisplatin treatment. The 
researchers then ran gene wide expression profiles on both OVCAR-8 cisplatin sensitive 
(OVCAR-8CS) and OVCAR-8 cisplatin resistant (OVCAR-8CR) cells grown in 3D (spheroids). 
Over three thousand genes were found to be differentially expressed between the paired cell line, 
many of which were possible STAT3 targets.  
I hypothesized that STAT3 plays a role in cisplatin resistance in ovarian cancer and 
developed two goals to investigate this role. The first goal was to look at STAT3 target genes 
involved in either EMT or evasion of apoptosis to assess if modulation of these genes would 
result in re-sensitization of OVCAR-8CR to cisplatin. The second goal was to treat OVCAR-
8CR spheroids with drugs identified as STAT3 inhibitors, alone and in combination with 
cisplatin, to determine if re-sensitization of OVCAR-8CR to cisplatin could be accomplished.  
None of the four STAT3 target genes chosen re-sensitized OVCAR-8CR spheroids to 
cisplatin. While this was disappointing, many more STAT3 target genes have yet to be 
investigated for their role in cisplatin resistance; therefore, it is still possible that STAT3 is 
playing a role in cisplatin resistance. While results of the first goal were disappointing, results of 
the second goal were successful. Five STAT3 inhibitors were tested (nifuroxazide, atovaquone, 
simvastatin, lovastatin and atorvastatin) and three, simvastatin, lovastatin and atorvastatin, have 
strong preliminary results of reducing OVCAR-8CR growth. Further research is needed into 
statins as ovarian cancer drugs, but their apparent effectiveness as STAT3 inhibitors in reducing 
OVCAR-8CR spheroid growth, highlights the pivotal role STAT3 is playing in cisplatin resistant 





General Background on STAT3: 
Signal transducer and activator of transcription 3 (STAT3) is part of a 7-member family 
of transcription factors (STATs 1, 2, 3, 4, 5a, 5b and 6), that are responsible for relaying signals 
from activated cytokine and growth factor receptors in the plasma membrane to the nucleus, 
where they are regulators of gene transcription1. In basal conditions, STATs are highly regulated, 
located in the cytoplasm in an inactive state, and activation from external stimuli is transient1. 
Activated STAT3 modulates transcription of many critical genes responsible for normal cellular 
functions such as regulation of apoptosis, differentiation, and proliferation.  
The janus kinase (JAK)/STAT signaling pathway is activated when an extracellular 
ligand, typically a cytokine from the interleukin (IL) family such as IL-6, binds to its 
corresponding receptor and brings the JAKs associated with the receptor into proximity to one 
another. Through a process called transphosphorylation, the JAKs phosphorylate each other’s 
tyrosine residues. This phosphorylation increases the activity of the JAK kinase domains, which 
then allow them to phosphorylate tyrosine residues located on the receptor, creating binding sites 
for other proteins that contain src homology-2 (SH2) domains, such as STAT3. Once STAT3 is 
bound to the receptor, it is phosphorylated by JAK at its tyrosine 705 residue (pY-STAT3), 
activating STAT3. STATs can also be activated by receptor tyrosine kinase epidermal growth 
factor receptors (EGFR) or non-receptor src type kinases2. Phosphorylation of STAT3 causes it 
to dissociate from the receptor and subsequently form hetero- or homodimers before the dimer 
translocates to the nucleus to induce transcription of target genes3 (figure 1.1).  Of note, 
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phosphorylation of STAT3 can also occur at serine 727 by members of mitogen-activated protein 
kinases (MAPK) and c-Jun N-terminal kinase (JNK), and has an ambiguous role4,5. Eventual 
dephosphorylation of STAT3 by phosphotyrosine phosphatases (PTPs) leads to inactivation of 
STAT3 and export from the nucleus6. 
 
Active STAT3 protein is present in tissues found throughout the body and is implicated 
in various roles that are vital for life in early development and functional maintenance of various 
tissues in adulthood. Mouse models have highlighted the importance of STAT3 in early 
embryonic development, as the absence of STAT3 results in a lack of embryogenesis and 
termination of fetal growth7. Typically, STAT3 prevents the untimely destruction of healthy cells 
by induction of pro-survival genes such as B-cell lymphoma-2L1 (BCL-xL) or inhibition of pro-
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apoptotic genes such as B-cell lymphoma-2-like protein 4 (BAX)8. In select cell types, STAT3 
has opposing effects as a promoter of apoptosis. In the case of mammary involution, leukemia 
inhibitory factor (LIF) activates STAT39 to promote apoptosis through increased expression of 
the pro-apoptotic genes BAX and BCL-2 anatagonist/killer (BAK)10. Additionally, STAT3 
induces the expression of genes, such as cyclin D1 (CCND1), that are involved in the 
progression of cells in the cell cycle from G1 to S phase11. In response to invading pathogens, 
IL-6 activates STAT3 to differentiate immune cells by induction of IL-21, which results in an IL-
21/STAT3 autocrine loop and subsequent induction of ROR-γt expression.  ROR-γt is a master 
regulator of Th17 (a member of the T helper cell family) cell differentiation
12,13. 
 
STAT3 in Cancer 
Many studies have demonstrated the role of constitutively active STAT3 in numerous 
cancers, including both solid tumors such as ovarian14, breast15, prostate16, and hematological 
cancers such as leukemias17 and lymphomas18. Evidence suggests that aberrant STAT3 signaling 
plays a role in promoting initiation and progression of cancers by regulating genes that allow the 
cancer cells to evade apoptosis, and to induce cellular proliferation, angiogenesis, and/or 
metastasis. In addition to the role of STAT3 in upregulating genes associated with cancer 
development and progression, STAT3 can create positive feedback loops by upregulating the 
transcription of cytokines and growth factors such as vascular endothelial growth factor (VEGF) 
and IL-619. STAT3 directly regulates VEGF, and increased expression of VEGF results in 
binding to vascular endothelial growth factor receptor 2 (VEGFR2), which subsequently results 
in activation of more STAT3. The resulting feedback loop has been linked to increased 
angiogenesis19,20. Activation of STAT3 can also occur through binding of cytokines, such as IL-6 
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to its receptor (IL-6R), which can subsequently lead pY-STAT3 to increase the expression of 
more IL-6. The combination of which can result in an autocrine positive feedback loop that leads 
to increased tumorigenesis21.  
 
Targeting STAT3 in cancer:  
While aberrant constitutive activation of STAT3 has been implicated in tumorigenesis of 
many cancers, reduction of STAT3 with synthetic or natural STAT3 inhibitors has been effective 
at inducing apoptosis of tumor cells. Though STAT3 is present in tissues throughout the body, 
and plays a critical role in many biological functions, murine in vivo and in vitro experiments 
have revealed that cells can survive without STAT37. The effectiveness of STAT3 inhibition 
against tumor cells, paired with the continued survival of tissues lacking STAT3, make it an 
attractive target for cancer therapy.  
The STAT3 signaling cascade provides ample opportunities to manipulate its activity as 
each step in the cascade serves as a potential target which includes inhibiting the ligand receptor 
complexes, inhibition of tyrosine phosphorylation, prevention of nuclear translocation of 
dimerized STAT3, inhibition of DNA binding and induction of phosphatases to dephosphorylate 
STAT322.  For example, Ruxolitinib is a JAK inhibitor with selectivity for JAK1/2 subtypes and 
it functions by inhibiting inappropriate JAK2 signaling that is observed in patients with 
myelofibrosis23. Stattic is a small molecule that interacts with the STAT3-SH2 domain, 
inhibiting STAT:STAT dimerization, nuclear translocation and transcriptional activity24,25. The 
compound S3-54A18 has been shown to bind directly to the DNA binding domain of STAT3, 
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inhibiting STAT3 activity26. In murine models, S3-54A18 has been effective at inhibiting lung 
tumor growth with minimal adverse side effects26.  
The JAK/STAT pathway offers multiple “druggable” opportunities that continue to be 
investigated. Ultimately, the goal is to find a drug that will treat chemosensitive and resistant 
cancer cells, with minimal side-effects. One approach that scientists are using to address the 
reduction of side effects is to repurpose medications that are already used for other conditions, 
and have known mechanisms of action, allowing for more targeted therapy. These medications 
can be identified utilizing two different screening methods: high throughput drug screening, and 
in silico screening.  
   
Nifuroxazide: 
A small molecule screen is a procedure by which a library of small molecules is 
systematically tested, either by one or several different assays, for their ability to activate, or 
inhibit a biological process of interest. Nelson et al. developed a high throughput cell-based 
assay aimed at identifying targeted inhibitors of STAT3 by measuring STAT3-dependent 
transcriptional activity in luciferase reporter STAT3-luc/U3A cells. To eliminate compounds that 
broadly inhibit gene expression, the researchers ran a luciferase reporter gene assay counter-
screen in parallel that used luciferase reporter cell line NF-kB-luc/293 cells to identify 
compounds that utilize NF-kB for transcriptional activity27. Using this technique, this group 
screened a library containing over 1,000 known bioactive compounds (Prestwick Library) and 
identified nifuroxazide; a compound used to treat acute diarrhea in other countries, as a potent 
STAT3 inhibitor27. Further research by Nelson et al. determined nifuroxazide was inhibiting 
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phosphorylation of STAT3 through the inhibition of JAK kinases in multiple myeloma and 
resulted in reduced viability of multiple myeloma cell lines and in patient samples27. Yang et al. 
confirmed the reduction of Y705 phosphorylated STAT3 and observed increases in apoptosis in 
nifuroxazide treated breast cancer cell lines. They also observed reduced tumor growth and lung 
metastasis in breast cancer mouse models28. Reduced STAT3 phosphorylation and associated 
increased apoptosis has also been observed in melanoma, colon carcinoma, hepatocellular 
carcinoma, osteosarcoma, thyroid carcinoma, leukemia, and pediatric tumors neuroblastoma and 
medullablastoma29. Its effectiveness in a broad spectrum of cancers, paired with the fact that it is 
already used in a clinical setting for other ailments, make nifuroxazide an attractive drug to study 
in ovarian cancer.   
  
Atovaquone: 
Xiang et al. sought to identify a novel STAT3 inhibitor utilizing an unbiased in silico 
approach by searching a database for compounds that reduced the expression of STAT3 genes.  
The Connectivity Map (CMap) is a cloud-based library containing over 1.5 million gene 
expression profiles from thousands of small molecules and genetic reagents that have been tested 
in various cell types30.  The researchers generated a 12-gene STAT3 activation signature that 
they queried in CMap and identified “hits” based off of compounds that were opposite to the 
STAT3 signature. The thought being that STAT3 gene expression drives STAT3-dependent 
cancer pathogenesis, therefore; STAT3 inhibitors could induce opposing gene expression31. The 
compound that had the most opposed gene expression was atovaquone; a Food and Drug 
Administration (FDA) approved antimicrobial drug used to treat Pneumocystis jirovecii 
pneumonia31. Through further in vitro studies, the research group was able to determine that 
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atovaquone appeared to be inhibiting the expression of gp130, the signal transduction subunit of 
the IL-6R that is therefore involved in JAK signaling. Without gp130 present to signal the 
JAK/STAT pathway, STAT3 phosphorylation cannot occur and STAT3 activation is inhibited31. 
To investigate the effectiveness of atovaquone as a cancer drug, Xiang et al. injected 
immunodeficient mice with human multiple myeloma cell line (U266) that has constitutively 
active STAT3. Once the mice formed plasmocytomas, atovaquone was administered orally. 
Atovaquone had minimal toxicity in mice, but treatment resulted in significant reduction in 
tumor growth and longer survival rates when compared to vehicle-treated mice31. Stevens et al. 
studied the effects of atovaquone on samples from pediatric patients with (AML). Patient-
derived products were injected into mice and mice later treated with atovaquone32. Overall, 
researchers observed slowed disease progression and prolonged survival in mice treated with 
atovaquone32.  These two studies highlight the effectiveness of atovaquone in cancer treatment 
and the potential it may have against ovarian cancer.  
 
STAT3 in Ovarian Cancer 
According to the American Cancer Society, approximately 21,410 women will receive a 
diagnosis of ovarian cancer, and 13,770 women will die from ovarian cancer in 2021. Ovarian 
cancer ranks fifth in all cancer deaths in women and is first in reproductive cancers. Late-stage 
diagnosis and associated metastasis and chemotherapy resistance attribute to these high mortality 
rates. Constitutive activation of pY-STAT3 is found in 70% of high-grade serous ovarian 
cancers, making it an attractive target for understanding its role in chemoresistance33.  
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Metastasis of ovarian cancer primary tumors in later stages of the disease result in 
secondary tumors present in the peritoneum of patients. This metastasis of tumors to the 
abdominal cavity are accompanied by the presence of ascites, or a buildup of fluid, in the 
patients. Samples of the ascites fluid taken from patients have found aggregates of tumor cells 
(spheroids) floating freely in an anchorage independent manner34,35. Since advanced stages of 
ovarian cancer take on a 3D morphology, recent in vitro studies have been utilizing spheroid 
models to better represent physiological conditions36.  
In addition to ovarian cancer cell spheroids, ascites fluid also contains a mix of secreted 
factors that can affect the cellular environment of the cancerous cells and the mesothelial cells 
located in the peritoneum. Secreted ECM molecules, cytokines, proteases and vascular 
permeability factors have all been detected in ascites fluid, and some have been shown to be 
driving factors of tumor growth and metastasis37. IL-6 has been observed in high levels in ascites 
fluid of ovarian cancer patients and has been associated with poor prognosis. IL-6 has also been 
implicated in ovarian cancer progression and chemotherapy resistance due to its activation of the 
JAK/STAT pathway and constitutive activation of STAT338.  
Saini et al. discovered that pY-STAT3 is constitutively expressed in the ascites fluid and 
ascites-derived cells of ovarian cancer patients. They also determined a correlation between 
expression levels of pY-STAT3 in the ascites-derived ovarian cancer cells (ADOCCs), and the 
aggressiveness of tumor growth and metastasis in mouse models39. Specifically, ADOCCs that 
expressed higher pY-STAT3 transplanted into mice resulted in larger tumors and widespread 
cancer throughout the peritoneum, while ADOCCs that expressed low or no pY-STAT3 had 
reduced tumor growth and no metastases39. Having determined pY-STAT3 was necessary for 
tumor progression in advanced ovarian cancer, Saini et al. moved to testing HO-3867; a novel 
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and selective STAT3 inhibitor. HO-3867 suppressed tumor growth, reduced angiogenesis and 
metastasis in their mouse model. HO-3867 was also determined to be effective against 
chemotherapeutic resistant human ovarian cancers freshly collected form patients39. Their 
research not only identified the necessity of pY-STAT3 in the aggressive nature of ovarian 
cancer, but confirmed it by selectively targeting STAT3 and reducing tumor growth, highlighting 
the therapeutic potential of inhibiting STAT3 in advanced ovarian cancer.  
 
Cisplatin 
In advanced stage ovarian cancer, the first line of treatment is surgery to remove the 
primary tumor and treatment with chemotherapy. Cisplatin is a commonly used and effective 
chemotherapeutic drug utilized to treat many cancers, including ovarian cancer40. Cisplatin is a 
platinum-based agent that works by cross-linking with DNA in the cell, causing DNA damage 
and eventual cell death41. Initial responses to cisplatin therapy in patients are promising, but soon 
they relapse due to resistance greatly reducing the drug’s effectiveness to fight the tumor cells. 
Previous research has suggested that the resistance of the cancer cells to drug treatment may be 
due to changes in the cells at the molecular level42. In ovarian cancer, aberrant STAT3 activation 
leads to cell migration and metastasis and evasion of apoptosis, suggesting that STAT3 may play 
a role in cisplatin resistance in ovarian cancer.  
Evading apoptosis  
Apoptosis, or programmed cell death, is a normal process that plays a vital role in several 
processes in the body, such as embryonic development43, cell turnover44 and evolution and 
function of the immune system45.  Improper function of this process is present in several 
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diseases, and evasion of apoptosis is a hallmark of cancer3,46. Apoptosis can be divided into two 
pathways: extrinsic and intrinsic.  
The extrinsic apoptosis pathway is triggered by a signal, typically a cytokine, released by 
a nearby cell, such as an immune cell, in response to adverse conditions in the extracellular 
matrix (ECM).. The ligand binds to its own particular death receptor (ex: FASL to FAS/CD95) 
leading to activation of procaspase 8 or procaspase 10. Activation of procaspase 8 to caspase 8 
then leads to cleavage of executioner caspases 3, 6 and 7. Finally, activated effector caspases 
lead to apoptosis3,47,48.  
Intrinsic apoptosis originates from inside the cell itself and is usually triggered by an 
internal stimuli, such as stress to the ER, DNA damage, metabolic stress or hypoxia, and is 
heavily regulated by the BCL-2 family of proteins3. BCL-2 proteins are well conserved, share 
BCL-2 homology (BH) domains and are made up of three classes: promoters of apoptosis, 
inhibitors of apoptosis, and regulators of apoptosis.  
In responding to lethal stimuli, the cell activates pro-apoptotic BH3 – only proteins, 
which in turn activate BAX and BAK. Activation of BAX and BAK results in the formation of 
pores in the mitochondrial membrane, allowing cytochrome c to be released3. The release of 
cytochrome c leads to its binding to apoptotic protease activating factor 1 (Apaf1) and the 
formation of the apoptosome complex. The apoptosome recruits and activates caspase 9 which 
subsequently activates executioner caspases 3, 6 and 7, leading to apoptosis3,49,50.  
As was discussed previously, when cancer hijacks the JAK/STAT pathway, STAT3 
becomes constitutively activated as tyrosine phosphorylated STAT3 (pY-STAT3) and begins to 
transcribe genes that aid in the survival of the cancerous tumor cells. Evasion of apoptosis, via 
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the upregulation of anti-apoptotic genes BCL-2 and BCL-xL, is one mechanism by which 
STAT3 promotes cancer51,52. Upregulation of BCL-2 and BCL-xL inhibits activation of BAX 
and BAK preventing the formation of the pores in the mitochondria thereby blocking apoptosis. 
This evasion of apoptosis is one mechanism in which cancer becomes resistant to therapy.  
One of the mechanisms of cisplatin resistance in ovarian cancer has been shown to be inhibition 
of apoptosis53,54. Cisplatin, works by interfering with DNA repair mechanisms, leading to DNA 
damage, which ultimately triggers the cell to undergo apoptosis41. Stage III/IV ovarian cancer 
tumors have increased levels of pY-STAT3, and therefore upregulated expression of pro-survival 
apoptotic proteins BCL-2 and BCL-xL. Increased expression of BCL-2 and BCL-xL allows the 
cancer to resist apoptosis that would otherwise be triggered by cisplatin, rendering it less 
effective3.  
 
Metastasis and Epithelial-to-Mesenchymal Transition 
Another less often studied mechanism of cancer resistance is the epithelial-to-
mesenchymal transition (EMT). By the time ovarian cancer is typically detected, it has already 
progressed to stage III/IV. This stage in cancer coincides with tumors that have begun, or already 
have, spread to other target tissues in the body. Metastatic cancers are more aggressive, tend to 
be more resistant to chemotherapy and account for 90% of cancer deaths46. Metastasis of cancer 
cells is possible because of EMT. 
EMT is a process by which epithelial (stationary) cells transform into mesenchymal 
(motile) cells and is a vital and normal process that is essential for early embryonic development 
and tissue remodeling during wound healing. Yet in cancer, this early embryonic trait is 
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reactivated to allow for organized epithelial cells to metamorphosize into more mobile, less 
organized and invasive mesenchymal cells. Changes to the epithelial cells include: the loss of 
cellular polarity, dedifferentiation, and changes in expression of cytokeratins and adherens 
junction proteins like E-cadherin and N-cadherin55.  
The more motile cells are then able to invade the circulation of the body (intravasation), 
either through the lymph or blood, travel to target tissues and subsequently leave the circulatory 
system to invade the target tissues (extravasation)55. Cells then go through a reverse process as 
described above for EMT, called the Mesenchymal-to-Epithelial Transition (MET). STAT3, 
along with other factors, both intrinsic and extrinsic, are involved in the initiation and reversion 
of EMT55.  
In ovarian cancer specifically, epidermal growth factor receptor (EGFR) tends to be 
overexpressed, leading to constitutively active STAT32. Constitutively active STAT3 leads to an 
increase in dissemination of ovarian cancer cells into the EGF-rich peritoneum. EGF is thought 
to elicit EMT events in ovarian cancer by upregulating the expression of TWIST1; a transcription 
factor oncogene that downregulates E-cadherin and upregulates N-cadherin55,56. E-cadherin is a 
molecule whose role is cell adherence. Loss of this molecule shifts the cells to a more motile 
state55–57. 
Additionally, IL-6 binding to the receptor, and subsequent STAT3 activation, has been 
shown to increase the expression of both TWIST1 and SNAI1/2 –a transcription factor oncogene 
that is shown to decrease the expression of E-cadherin58. It has recently been suggested that, in 
breast cancer, a positive feedback loop exists where the upregulation of TWIST1 leads to 
upregulation of IL-6, leading to autocrine activation of STAT3. The activation of STAT3 by IL-6 
has also been shown to promote the selection and proliferation of CD44high/CD24low cells, which 
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have stem-cell like properties. These properties have been found to be present in post-EMT 




Unlike many cancers, metastasis of ovarian cancer can occur without the need of 
vasculature as a means of movement through the body. Ovarian cancer tumor cells that have 
sloughed off the primary tumor and entered the peritoneal cavity have the ability to block 
lymphatic drainage by secreting vascular permeability factors, which subsequently lead to a 
buildup of ascites fluid37. Within the fluid, ovarian cancer cells can remain as single cells or they 
can aggregate to form spheroids. The peritoneal cavity and the organs contained within are 
bathed with the built-up ascites fluid containing the cancer cells and spheroids, which 
subsequently invade mesothelial cells lining the peritoneum and its organs, resulting in 
secondary tumors37.  
Interestingly, secondary tumors do not adhere to mesothelial cells lining the peritoneum 
and its organs, but rather to connective tissue located beneath the mesothelial layer59. Iwanicki et 
al. discovered that force generation on the mesothelial cell-associated ECM encouraged the cells 
to migrate away from the tumor (mesothelial clearance), allowing it to attach to the connective 
tissue beneath. Davidowitz et al. revealed that ovarian cancer cells that were enriched with 
mesenchymal genes promoted strong clearance while ovarian cancer cells expressing epithelial 
genes had weak or undetectable clearance. They were able to do this utilizing a mesothelial 
clearance assay where they observed ovarian cancer spheroids clear a monolayer of LP9 
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mesothelial cells (figure 1.2). The researchers overexpressed known EMT transcription factors 
TWIST1, SNAI1 and ZEB1 in cell-lines with weak clearance activity, which promoted stronger 
clearance. Conversely, knockdown of TWIST1 and ZEB1 transcription factors in cell-lines with 
strong clearance activity resulted in lessened clearance60.   
 
This research gave insight into the role of EMT genes in the metastatic behavior of 
ovarian cancer cells and the effect that reducing the mesenchymal state of these cells may have 
on the progression of the disease. As was previously mentioned, constitutive activation of 
STAT3 by IL-6 can lead to the overexpression of EMT transcription factors TWIST1 and 
SNAI1/2 and subsequent mesenchymal expression of ovarian cancer cells58. The connection of 
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STAT3 to increased mesenchymal gene expression and the associated increased disease 
progression further highlight STAT3 as an attractive target in ovarian cancer.   
 
Model of Cisplatin Resistance 
Recently, Chowanadisai et al. conducted a study comparing gene expression in  cisplatin-
sensitive OVCAR-8 (OVCAR-8CS) cells versus cells that have been adapted to be cisplatin-
resistant (OVCAR-8CR). They chose OVCAR-8 cells because not only do they readily form 
spheroids in culture, but they also model the heterogeneity of high-grade serous ovarian cancer 
(HGSOC) and are mutant for p5336.  
The researchers grew both cell lines in 3D spheroids using a low attachment agarose gel 
scaffold before isolating total RNA and running genome-wide gene expression profiles via 
microarray analysis. Overall, 3,331 differentially expressed probesets coding for 3,139 distinct 
protein-coding genes were identified between OVCAR-8CS and OVCAR-8CR cell lines, with 
OVCAR-8CR cells showing significant enrichment for genes with a mesenchymal gene 
expression signature36. In ovarian cancer, a mesenchymal state is associated with drug resistance 
and reduced patient survival rate61. 
One of the genes identified by Choawandasi et al. was YAP1, a regulator of the Hippo 
signaling pathway (involved in repair, growth and homeostasis of cells). YAP1 was expressed 3x 
higher in the OVCAR-8CR versus OVCAR-8CS cells. OVCAR-8 cells are KRAS mutant, and it 
is suggested that the YAP1 gene may be working in conjunction with KRAS activation to drive 
resistance to cisplatin36. 
16 
 
Chowanadisai et al. continued their research by performing gene set enrichment analysis 
(GSEA) to identify specific pathways that may be mediating resistance in the OVCAR-8CS and 
OVCAR-8CR cell line. Many differentially expressed pathways were identified, including those 
involved in regulation of apoptosis, inflammation response (including increased expression of 
IL-6), and the Jak/STAT3 pathway36. This raised the possibility that STAT3 could be playing a 
role in cisplatin resistance.   
Prior to my arrival in Sarah Walker’s lab, additional GSEA was carried out with a 
STAT3 specific gene list62 that was distinct from the JAK/STAT3 pathway gene list produced by 
Chowanadisai et al. Dr. Walker then utilized the gene expression data from Chowanadasi et al, 
and verified that STAT3 genes were enriched in the resistant OVCAR-8 cells. Additionally, a 
former undergraduate student in the Walker lab, Brittnee Wirth, examined how STAT3 was 
involved in cisplatin resistance by overexpressing STAT3 in OVCAR-8CS spheroids before 
exposing them to different concentrations of cisplatin. Brittnee found that overexpressing STAT3 
in the sensitive spheroids resulted in a reduced response of the OVCAR-8CS cells to cisplatin, 
effectively promoting resistance and supporting the bioinformatics data performed by Sarah 




Considering the experiments performed prior to my arrival, I hypothesized that STAT3 
was promoting cisplatin resistance in ovarian cancer. I planned to test this hypothesis in two 
concordant ways. The first goal was to identify STAT3 target genes that were responsible for the 
cisplatin resistant phenotype. The second goal was to identify STAT3 inhibitors that re-sensitize 
the resistant OVCAR-8 spheroids to cisplatin.   
The first goal was accomplished by combining gene expression data from Chowanadasi 
et al. with publicly available STAT3 ChIP-seq data to find specific STAT3 target genes 
upregulated in the resistant OVCAR-8 cells. While many were discovered, I chose four that have 
been linked to EMT to conduct additional experiments. I chose EMT affiliated genes because of 
the connection of EMT and cisplatin resistance, as was previously described. I investigated the 
differences in expression levels between sensitive and resistant OVCAR-8 spheroids. I also 
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conducted several siRNA experiments investigating how modulation of the STAT3 target genes 
changed the morphology of the spheroids themselves and the sensitivity of the resistant 
OVCAR-8 spheroids to cisplatin treatment.  
The second goal was accomplished by testing drugs that had been previously identified as 
STAT3 inhibitors, either through drug screening by other research groups (Nifuroxazide)27 or by 
in silico search queries by Xiang et al. (Atovaquone)31 and Brendan Reilly utilizing Connectivity 
Map (Broad Institute) (Lovastatin, Simvastatin and Atorvastatin). Drugs were examined either 


















Materials and Methods: 
Cells Used:  
Human mesothelial cells, LP9, were provided by Martin Sattler, Dana-Farber Cancer 
Institute. Mesothelial cells were cultured in 50% M199/50% medium 106, with 15% iron-
enriched calf serum, 10 ng/ml EGF, 0.4 μg/ml Hydrocortisone, and pen strep. Human ovarian 
cancer cell line, OVCAR-8, was generously provided by Ronnie Drapkin, Dana-Farber Cancer 
Institute. Paired cisplatin sensitive and resistant OVCAR-8 cell lines (OVCAR-8CS and 
OVCAR-8CR) were graciously provided to us by Alexander Brodsky from Brown University.  
Human ovarian cancer cells were grown in monolayers and cultured in RPMI 1640 medium 
supplemented with 10% fetal bovine serum. All cells were incubated at 37°C and 5% CO2.      
Adaptation of cisplatin resistant OVCAR-8 cells: 
During early experimentation with the paired cell lines, I noticed that the OVCAR-8CR 
cells weren’t behaving as expected and were no longer resistant to cisplatin. Therefore, it became 
necessary to re-create the resistant OVCAR-8CR cells. Cisplatin (cis-
diamminedichloroplatinum(II)) formulated in a 3.33 mM solution, was purchased from the 
Dana-Farber Cancer Institute pharmacy, and stored at room temperature (RT). OVCAR-8CR 
cells were created by adapting OVCAR-8CS cells to grow in vitro in the presence of cisplatin. 
This was done by exposing and culturing the cells to cisplatin in a stepwise fashion, in 
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increments of 0.5uM, up to 3uM maximum dosing. Starting at 1uM cisplatin supplementation in 
standard RPMI medium, cells were split and cultured for two weeks before increasing the 
concentration of cisplatin supplementation. Resistance was confirmed by viability testing, where 
the OVCAR-8CS cells showed a 2-fold greater sensitivity to cisplatin when compared to the 
adapted OVCAR-8CR cells.  
Inhibitors used:  
Atovaquone (AQ) was obtained from Sigma Aldrich and was dissolved in dimethyl 
sulfoxide (DMSO) to a stock concentration of 12.5mM. Nifuroxazide (Nifu) was obtained from 
Millipore and was dissolved in DMSO to a stock concentration of 5mM. Atorvastatin was 
obtained from Selleckchem and was resuspended in DMSO to a stock concentration of 10mM. 
Simvastatin and Lovastatin were obtained from Medchem Express and were dissolved in DMSO 
to a stock concentration of 10mM. STAT3 inhibitors listed above were stored at -20°C.  
Short hairpin RNAs (siRNAs) used: 
Short hairpin RNAs (siRNAs) were used for knockdown experiments with STAT3 target 
genes and included, siControl (Sigma Aldrich), siSTAT3 (Life Technologies), siSNAI2 (Sigma 
Aldrich), siKLF6 (Sigma Aldrich), siPXN (Santa Cruz), siUGCG (Santa Cruz). 
siRNA Transfections: 
Reverse transfection of OVCAR-8CS and OVCAR-8CR was performed by premixing 
INTERFERin® transfection reagent (Polyplus), siRNAs (Appendix A) and Opti-MEMTM 
reduced serum medium (GIBCO) together and incubating at room temperature (RT) for 20 
minutes prior to addition to cell culture plates. Cells were then added at predetermined 
concentrations to the transfection reagent containing culture plates. siRNA was utilized in 
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viability assays (48hr treatment prior to addition of compounds) and RNA/protein isolation (48-
72hr treatment).  
Measuring viability:  
OVCAR-8CS and OVCAR-8CR cells were plated at the same concentration (50uL of 
suspension at 3.5x103 cells per well) in ultra-low adhesion (ULA) u-bottom 96-well plates 
(Greiner). Cells were incubated for 48 hours to encourage spheroid formation within each well. 
2x concentrated compounds of interest were then added in 50uL of medium at varying 
concentrations (uM) to wells, and plates were incubated for an additional five days (120 hours).  
Viability was assessed utilizing different assays. CellTiter-Glo 3D (CTG) (Promega) is a 
luciferase assay that lyses spheroids present in the assay plate and produces a luminescent signal 
based off of the ATP present from viable cells. Luminescent readings were acquired using a plate 
reader (Molecular Devices M2e). Data was exported to Excel where results were averaged before 
importing into GraphPad Prism 6. Once in GraphPad, analysis utilizing two-way ANOVA with 
multiple comparison and Tukey correction was used to assess significance between results.  
Observing cell morphology: 
NucBlue and propidium iodide (PI) cell stains (ReadyProbesTM Cell Viability Imaging 
Kit, Blue/Red – ThermoFisher Scientific) were added to wells to qualitatively assess cell 
viability and morphology of the spheroids. NucBlue stains the nucleus of all cells present in the 
culture and fluoresces blue using a standard DAPI channel. Propidium iodide can only stain the 
nuclei of dead cells that have damaged cellular membranes, and it fluoresces red. Caspase 3/7 
stain (CellEventTM Caspase 3/7 Green ReadyProbesTM Reagent – ThermoFisher Scientific) was 
added to spheroids to gather additional qualitative information into the mechanism of cellular 
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death. Caspase 3/7 fluoresces green and is present in cells that are undergoing early apoptosis. 
These three stains were imaged utilizing an EVOS microscope (EVOS FL Auto 2 – Invitrogen) 
and/or a Nikon confocal microscope (A1R laser scanning Confocal Fluorescence Microscope) 
and assisted in visualizing the morphology of how spheroids were responding to drug treatments.  
Clearance Assay: 
On day one, OVCAR-8CS and OVCAR-8CR cells were stained using 1,1’-Dioctadecyl-
3,3,3’,3’-Tetramethylindocarbocyanine Percholate (Dil) (orange)(Thermo life tech) stain. 
Dil/3,3’-Dioctadecyloxacarbocyanine Percholate (DiO)(green)(Thermo life tech) stains are light 
sensitive, so all steps were completed with room lights off. Cells were placed in a 15mL conical 
at a concentration of 1x106 cells/ml and 5uL of stain was added to cells and incubated at 37°C 
for 20 minutes. Cells were spun at 1500 RPM for 5 minutes. Supernatant was removed and 1mL 
phosphate-buffered saline (PBS) added to cells. Cells were mixed before repeating “spin and 
wash” steps two more times. Once stained, cells were plated in 96 well ULA plates. When 
looking at clearance in cells that have been treated with siRNA, siRNA is added to the 96 well 
plates ahead of the cells. On day two, LP9 cells were stained utilizing the same staining 
procedure above, in DIO (green) stain. LP9 cells were plated in a 96 well flat bottom tissue 
culture treated plates to encourage 2D growth of the cells. They were plated at 1.1x105 cells per 
well to ensure confluency by day three. On day three, medium was removed from LP9 cell 
containing wells. To prevent drying out the LP9 cells, this was done one row at a time. Spheroids 
and their media were then moved from the 96 well ULA u-bottom plate, to the 96 well plate 
containing the LP9 cells. Co-cultures were then imaged at 0 hours, and again at 24 hours on the 




Primers used for gene expression studies: 
 
Analysis of gene expression: 
Cells that had been incubating for 48-72 hours after plating were isolated using slightly 
different methods depending on if those cells were plated in adherent (2D) or ULA (3D) plates. 
For cells grown in 2D, medium was aspirated off and replaced with 1mL cold PBS. Cells were 
removed by physical means using cell scrapers. Dislodged cells were then gently pipetted into 
1.5mL tubes and spun in the centrifuge to form pellets.  
Cells grown in ULA plates were pipetted into 5mL tubes and spun (3000RPM for 5min) 
to pellet spheroids. Media was carefully aspirated and 1mL ice cold PBS added to resuspend and 
wash the spheroids. The volume was moved to 1.5mL tubes and spun in the centrifuge to pellet 
the sample.  
Once cells, whether 2D or 3D, had been pelleted in the 1.5mL tubes, PBS was removed 
from pelleted cells and 300uL RNA lysis buffer was added and pellets were agitated to 
encourage lysing of the sample. The tubes were centrifuged and lysates moved to Zymo spin 
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columns for purification of total RNA using the Quick-RNA Miniprep Kit (Zymo Research) – 
manufacturer protocol was followed with skipping the DNase I optional treatment step. 
Quantification of total RNA was measured utilizing the QubitTM RNA BR (Broad-Range) Assay 
Kit (Invitrogen) read out on the Qubit 4 Fluorometer (Invitrogen). Samples were stored at -20°C.  
Total RNA was reverse transcribed using TaqManTM reverse transcription reagents (Invitrogen 
and placed on the Pelitier Thermal Cycler PTC-200 (MJ Research – Waltham, MA). cDNA was 
mixed with water and Power SYBR Green PCR Master Mix (Applied Biosystems) before 
addition of selected primers (see appendix A) and aliquoting into either 96-well or 384-well PCR 
plates. cDNA was then assayed by real-time polymerase chain reaction utilizing either the 7500 
Fast Real-Time PCR System (Applied Biosystems) for 96-well plates, or the ViiA 7 Real-Time 
PCR System (Applied Biosystems) for 384-well plates. Data was exported into Microsoft Excel 
and analyzed using the ∆∆CT method. The ∆∆CT method is used to compare the relative 
expression of mRNA to an internal control, in our case, Actin. The ∆∆CT was normalized for 
graphing, with the control set to 1. In experiments comparing OVCAR-8CS to OVCAR-8CR, the 
Actin control used for normalization was that assigned to the OVCAR-8CS cell line. When 
comparing the paired cell line in 2D versus 3D, the OVCAR-8CS 2D cell line treated with Actin 
for each replicate was used to normalize its OVCAR-8CR from the same replicate. Data were 
exported to Excel where reaults were averaged before exporting to GarphPad Prism 6. Additional 
analysis to determine significance between results was conducted within GraphPad and varied 
slightly depending on the data. Either t-test (one per row) analysis to the corresponding control 





Protein isolation/Western Blot: 
Cells that had been incubating in treatment conditions for 48-72hrs were collected 
according to above mentioned (RNA isolation) techniques depending on whether they were 
grown in 2D versus 3D. Once samples had been washed and pelleted in cold PBS, PBS was 
carefully aspirated off and replaced with either 30uL (3D samples) or 50uL (2D samples) of 
EBC lysis buffer (50mM Tris, 250mM NaCl, 0.5% NP40) containing protease and phosphatase 
inhibitors. Samples were incubated on ice with lysis buffer for 15 minutes before spinning 
samples in a centrifuge (14,000rpm for 10min at 4°C). Samples were moved to fresh labeled 
tubes on ice before quantification. Total protein was quantified utilizing the Qubit Protein Kit 
Assay (Invitrogen) and measured using the Qubit 4 Fluorometer (Invitrogen). Quantitated protein 
samples were diluted in a fresh mixture of 2x Laemmli sample loading buffer and 10% 2-
mercaptoethanol (BME) then boiled (100°C for five minutes) before loading 30ug of protein 
from each sample into each well of an 8% polyacrylamide gel. Gels are poured in house and used 
within a month of pouring. Precision plus protein dual color standards molecular weight marker 
(Bio-Rad – Hercules, CA) was loaded into the first well of each gel that was run as a reference 
marker. Heya8 cells stimulated with IL-6 produce high levels of tyrosine phosphorylated STAT3 
and was used as a positive control for all experiments where we measured pY-STAT3 levels.  
Gels were loaded into the buffer tank and 1x of a 10x running buffer added. Gel was run at 200 
volts for approximately 60 minutes or until the loading dye ran off the gel. The gels were rinsed 
with water to remove as much SDS as possible. 1L fresh transfer buffer at 1x concentration 
(720mL dH2O, 80mL 10x Transfer buffer, 200mL Methanol) was used to transfer protein bands 
to nitrocellulose.  While transfer was occurring, blocking buffer was made by taking 1x TBST 
(10mL 1M Tris pH 8.0, 10mL 5% Tween, 30mL NaCl and dH20) and adding it to powdered 
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milk. Quality of the transfer and protein loading was checked via Ponceau S solution by rocking 
the nitrocellulose membrane in Ponceau for approximately one minute. The membrane was 
rinsed with water until bands appear. Nitrocellulose membrane was then rocked in blocking 
buffer for one hour. The membrane was rinsed to remove excess milk in 1x TBST before 
addition of primary antibody (pY-STAT3, STAT3 Cell Signaling; tubulin Sigma) to the 
nitrocellulose membrane, which was made up at 1:10,000 dilution in 1x TBST. Primary was 
rocked for an hour at room temp before placing at 4°C overnight. The next morning, the 
membrane was rinsed three times in 1x TBST (5 minutes per wash) and horseradish peroxidase 
(HRP)-conjugated secondary antibody was added (1:5,000 - 1:10,000 dilution). The membrane 
was rocked for an hour at room temperature in secondary before washing three times in 1x 
TBST. Enhanced chemiluminescent (ECL) reagent (Western Lightening Plus ECL – 
PerkinElmer) was added to the nitrocellulose membrane and rocked for one minute before 
dabbing excess liquid from the membrane and wrapping it into plastic wrap. The blot was then 
placed into a cassette and film developed in a darkroom using an x-ray film processor 
(ECOMAX, GmbH & Co. – Germany). Film was scanned and uploaded into ImageJ online 
software where the protein bands were quantitated. Generated numbers were exported to Excel to 
be averaged and normalized before importing into GraphPad Prism 6. Statistics was performed 
using one-way ANOVA with multiple comparisons and Tukey correction.  
Results for goal 1: Identification of STAT3 target genes that are responsible for the 
resistant phenotype:  
Knowing that STAT3 has been linked to chemoresistance and is active in 70% of high-
grade serous ovarian cancers (HGSOCs), I wanted to determine the role that STAT3 was playing 
in cisplatin resistance. Chowanadasi et al. developed a 3D cisplatin resistance in vitro model 
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with OVCAR-8 ovarian cancer cells, that contained many similar features of HGSOC 
tumors36,63,64.  
  We obtained the OVCAR-8CS/OVCAR-8CR cells36 for our experiments; however, over 
time I found that these cells were no longer resistant to cisplatin. Therefore, I adapted the 
obtained OVCAR-8CS cells in-house to cisplatin utilizing the same methods as Chowanadisai et 
al.  
OVCAR-8CR cells are resistant to cisplatin  
To determine if the OVCAR-8CS cells were successfully adapted to resist cisplatin, 
viability comparing OVCAR-8CS and OVCAR-8CR cell responses to different doses of 
cisplatin in 3D was performed (figure 2.1). The concentration at which 50% of the cells were 
viable, or the half maximal effective concentration (EC50) of cisplatin in the OVCAR-8CS 
spheroids was repeatedly found to be 3uM. Treatment of these spheroids at 5uM did not show an 
increase in toxicity when compared to 3uM cisplatin. Cytotoxic responses of OVCAR-8CS 
spheroids to 3uM and 5uM cisplatin were significant at P < 0.0001 in both cases. OVCAR-8CR 
spheroids displayed resistance of cisplatin treatment at both 3 and 5uM. At 3uM cisplatin 
treatment, there was an approximate 2-fold difference in relative cell growth, where OVCAR-
8CR showed little death from cisplatin, and OVCAR-8CS showed more than 50% death. From 
this data, we confirmed that our adapted OVCAR-8CR cell line was resistant to cisplatin in 3D 
culture. I used the OVCAR-8CS and OVCAR-8CR paired cell line for future experiments, as a 
sensitive and resistance model for cisplatin in vitro. With the adaptation of resistant OVCAR-8 
cells to cisplatin complete, I moved to determine if my resistant cells had enhanced clearance 





Cisplatin resistance enhanced clearance of LP9 monolayers  
Chowanadasi et al. had identified many EMT genes enriched in the resistant OVCAR-8 
cells, and Davidowitz et al. discovered EMT genes played an important role in clearance of 
mesothelial cells and subsequent adherence of secondary tumors in ovarian cancer. Therefore, I 
wanted to further confirm that my newly adapted cells also had enhanced EMT compared to the 
OVCAR-8CS cells. I decided to measure differences in EMT by assessing the differences in the 
invasiveness of my paired OVCAR-8 cells utilizing a mesothelial clearance assay.  
It has been previously observed that ovarian cells and spheroids adhere to connective 
tissue located beneath the mesothelial cells lining the peritoneum, by effectively clearing the 
mesothelial cells in their way59. The mesothelial clearance assay is an in vitro assay that models 
the interaction of ovarian cancer spheroids and mesothelial cells in vivo65. Different dyes are 
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used to distinguish spheroid-forming ovarian cancer cells from mesothelial monolayers. After 
growth of each cell line has been established, spheroids are moved to mesothelial monolayers 
and images are taken on a microscope to track clearance of the spheroids into the monolayer. 
Clearance is visualized by the space devoid of cells in the mesothelial cell monolayer created by 
the spheroid65. This approach can answer the question of whether or not OVCAR-8CR cells are 
more invasive than OVCAR-8CS cells.   
In figure 2.2, LP9 monolayers were observed underneath spheroids for both OVCAR-
8CS and OVCAR-8CR at 0 hours. At 24 hours, OVCAR-8CS spheroids had pushed aside the 
LP9 monolayer and there was a dark space surrounding the area where the spheroid had invaded. 
The dark space was representative of where the outer surface of the spheroid occupied. When 
looking at the trans light of the well, the spheroid appeared to be stretching into more of an oval 
shape and had portions of the outer layer of the spheroid that were outstretched and possibly 
looking to move outward more.  
OVCAR-8CR spheroids also cleared the LP9 monolayer at the 24-hour timepoint. The 
dark space surrounding the area of spheroid invasion was present again, however, this space 
appears to be larger than the spheroid itself. Similar to its OVCAR-8CS counterpart, OVCAR-
8CR spheroids had portions of its outer membrane stretched out in what could be an attempt to 
invade the LP9 cells further. The OVCAR-8CR spheroids appeared to have invaded the LP9 
mesothelial layer, clearing more area around itself compared to the OVCAR-8CS spheroids. This 
observation supported my hypothesis that OVCAR-8CR spheroids would be more invasive than 
OVCAR-8CS spheroids. Having confirmed cisplatin resistance and increased EMT phenotype in 
OVCAR-8CR cells compared to OVCAR-8CS cells, I moved to assess differences in pY-STAT3 






Increased pY-STAT3 protein levels observed in 3D spheroids  
Considering bioinformatics data suggested an increase in STAT3 activity in cisplatin 
resistant cells, I wanted to determine if  OVCAR-8CR cells had increased pY-STAT3 levels 
compared to OVCAR-8CS cells. Since, STAT3 protein is approximately 86 kDa, I analyzed the 
band that migrated to that region (determined by comparison with a molecular weight protein 
ladder), which corresponded to the location of pY-STAT3 in our positive control sample (figure 
2.3).  I found that in two of the three replicates, increases in pY-STAT3 levels were observed in 
cells grown in 3D compared to 2D. However, no clear differences were observed in pY-STAT3 
levels between OVCAR-8CS and OVCAR-8CR cells grown in 3D. When densitometry was 
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performed across all three replicates, there was no significant difference in pY-STAT3 protein 
levels in 2D versus 3D or in OVCAR-8CS versus OVCAR-8CR. With no clear identification of 
increased pY-STAT3 levels between samples, I decided to switch my focus to identifying 
potential STAT3 target genes enriched in the OVCAR-8CR cells.  
 
 
Identification of STAT3 target genes of interest. 
Without clear identification of increased pY-STAT3 expression in OVCAR-8CR cells 
compared to OVCAR-8CS cells and considering that measurement of total pY-STAT3 levels in 
cells might not be representative of pY-STAT3 that has translocated to the nucleus to transcribe 
target genes of interest, I moved my focus to understanding what STAT3 target genes could be 
responsible for promoting the cisplatin resistance phenotype. I analyzed microarray data from 
Chowanadasi et al. and merged this data with breast tumor STAT3 ChIP-seq data from GEO 
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GSM2278006. Breast tumor data was used due to a lack of publicly available ovarian cancer 
ChIP-seq data, and because breast cancer has similar roles for STAT3 to ovarian cancer in the 
way it promotes both tumor types. Additionally, we have (unpublished) data showing binding of 
STAT3 in breast and ovarian cellsat many similar binding sites by directed ChIP. I then 
identified potential STAT3 target genes by identifying STAT3 binding peaks near these genes, 
suggesting that STAT3 regulates these genes (figure 2.4). Though not the only genes identified, I 
selected SNAI2, KLF6 and PXN, which were all linked to roles in EMT and metastasis, and 
UGCG for its connection with multi-drug resistance in ovarian cancer (MDR) 
Cancer cells that have metastasized and have therefore gone through EMT and 
subsequent MET, have increased stem-cell like properties and express the characteristics of 
increased pluripotency, tumorigenicity and chemoresistance55. Cells that are post-EMT and have 
acquired stem cell features have also been associated with resistance to apoptosis.66 Since 
cisplatin causes crosslinking in DNA and subsequent damage that leads to apoptosis; and 
resistance to apoptosis has been linked to post-EMT and chemotherapy resistant cancer cells, I 
chose to investigate three STAT3 target genes linked to the EMT phenotype to link the role 
STAT3 has in chemotherapy resistance in ovarian cancer67.    
Snail family transcriptional repressor 2 (Slug/SNAI2) gene is a zinc finger transcription 
factor that acts as a repressor of transcription and binds to E-box motifs. It is thought to repress 
the transcription of E-cadherin in breast carcinoma and has antiapoptotic activity. Repression of 
E-cadherin is a hallmark of the EMT process, therefore SNAI2 is also thought to play a role in 
EMT.68  Kruppel like factor 6 (KLF6) is part of a family of zinc-finger transcription factors that 
regulate differentiation and development through signal transduction pathways for apoptosis, cell 
proliferation and angiogenesis69. KLF6 has been shown to contribute to EMT and metastasis in 
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breast cancer70. Lastly, Paxillin (PXN) is a scaffolding protein and main component of focal 
adhesions (FA) that, when phosphorylated, recruit structural and signaling molecules involved in 
cell migration and movement. It also plays essential roles in inflammation, cancer development 
and metastasis.71  
Ceramide is a lipid second messenger that functions by inducing mitochondrial apoptosis 
and arrests the growth of cancer cells.72 UDP-glucose ceramide glucosyltransferase (UGCG) is a 
key enzyme in the first step of glycosphingolipid (GSL) biosynthesis, which generates 
glucosylceramide by attaching a glucose molecule to ceramide and is the precursor for all GSL.68 
Overexpression of UGCG has been linked to multi-drug resistance (MDR) in many cancers, 
including ovarian cancer.68,72,73 The mechanism by which UGCG overexpression is associated 
with MDR is still being researched; however, it is thought to be involved with the clearance of 






siSTAT3siSTAT3 reduces expression of UGCG and KLF6 
Having identified potential STAT3 target genes that could be contributing to the resistant 
phenotype of our cells, I wanted to confirm their link to STAT3 by silencing STAT3 and 
measuring mRNA expression of our genes of interest (n=4). I believed that genes that were 
affiliated with STAT3 would have reduction in mRNA expression. I compared all mRNA 
expression relative to siControl, which was set to one. Any gene that had mRNA expression 
below one in response to siSTAT3, was considered a confirmed target of STAT3 (figure 2.5A).   
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Silencing STAT3 in our OVCAR-8 cells was successful in replicated experiments as 
every data point was significantly reduced compared to siControl (P < 0.0001); well below the 
siControl of 1. UGCG and KLF6 both had reduced mRNA expression with siSTAT3. UGCG had 
a large error bar present due to one data point that was higher than the other three data points. 
Because the majority of the points were reduced compared to the control (figure 2.5B), I had 
confidence that UGCG is a STAT3 target gene. KLF6 had very reproducible and significant (P < 
0.01) results, with all four points falling below the siContol of 1, indicating KLF6 is also a 
STAT3 target gene. SNAI2 data varied, with two points below and two points above 1. While the 
results were inconsistent, I proceeded with studies of SNAI2 being a STAT3 target gene because 
two results showed reduced expression. PXN results also varied widely. Two results were 4-fold 
higher than the control, showing a large increase in mRNA expression in response to siSTAT3.  
Another result was very low, and the last point had no change from the control (figure 2.5B). 
Though I could not say with confidence from this experiment that PXN is a STAT3 target gene, 
modulation of PXN mRNA expression was present in response to siSTAT3. Therefore, I decided 




STAT3 target genes are upregulated in OVCAR-8CR spheroids 
Having determined modulation of mRNA expression of selected target genes with 
siSTAT3, I measured differences in mRNA expression of these target genes in OVCAR-8CS and 
OVCAR-8CR grown in both 2D and 3D. Knowing that previous bioinformatics studies revealed 
increased expression of STAT3 target genes in the resistant OVCAR-8 spheroids, I expected to 
see increased STAT3 target gene expression in resistant OVCAR-8 spheroids. UGCG and KLF6 
had previously been confirmed as STAT3 target genes in siSTAT3 RTPCR experiment (figure 
2.5), so I expected to specifically observe increased mRNA expression of these two genes in 
resistant versus sensitive spheroids. Results were normalized to OVCAR-8CS 2D cells. (figure 
2.6)  
STAT3 mRNA expression increased in OVCAR-8CS 3D spheroids when compared to 
OVCAR-8CS 2D cells. There was also a small increase observed in STAT3 mRNA expression in 
OVCAR-8CR 3D spheroids compared to OVCAR-8CR 2D cells. There was very little difference 
in STAT3 mRNA expression between OVCAR-8CS 3D and OVCAR-8CR 3D spheroids. Both 
OVCAR-8CS and OVCAR-8CR grown in 3D are elevated in comparison to 2D and have similar 
expression levels. These observations were not significant in any comparison and did not support 
my hypothesis. 
UGCG had a significant increase in mRNA expression in OVCAR-8CS 3D compared to 
2D and compared to OVCAR-8CR 2D and 3D. While there was significant differences observed 
in OVCAR-8CS 3D and OVCAR-8CR 3D (P < 0.001), the effect was the opposite of what was 
hypothesized where OVCAR-8CR 3D had less expression than OVCAR-8CS 3D. KLF6 had 
increased mRNA expression in both OVCAR-8CR 2D (P value < 0.0021) and 3D (P value < 
0.0057) when compared to the OVCAR-8CS 2D control, but no significant difference was 
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observed in OVCAR-8CS 3D. There was also no significant difference observed between 
OVCAR-8CS 3D and OVCAR-8CR 3D.  
SNAI2 had the most change in mRNA expression with significant increases observed in 
both OVCAR-8CS 3D spheroids when compared to OVCAR-8CS 2D cells (P value < 0.007), 
and OVCAR-8CR 3D spheroids when compared to OVCAR-8CR 2D cells (P value < 0.0005). 
From this data, I could conclude that SNAI2 expression is increased in the OVCAR-8CR cells. I 
can also state that 3D growth of either OVCAR-8CS or OVCAR-8CR cells had a significant 
impact on the expression of SNAI2. PXN did not appear to show much difference in expression 
between the cell lines and growth conditions tested. Overall, the gene expression levels of 
STAT3 target gene SNAI2 correlated with my hypothesis for this experiment. SNAI2 mRNA 




siRNA to STAT3-target genes reduces their expression  
Having identified STAT3 target genes in our OVCAR-8CR cells, I wanted to determine 
the effects of these target genes on the growth of these cells in 3D. To do this, I first needed to 
investigate differences observed with STAT3 target genes when these genes were silenced using 
siRNA in OVCAR-8CS and OVCAR-8CR in 3D only (figure 2.7). Looking at 3D growth alone 
allowed me to focus on potential STAT3 target gene effects in the clinically relevant spheroid 
model established by Chowanadasi et al.   
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Knockdown of STAT3 and STAT3 target genes was successful as significant (P < 0.0001) 
decrease in mRNA expression of  silenced genes was measured compared to the OVCAR-8CS 
siControl. This was reproducible (n=3) with small error bars further giving me confidence in the 
results. I also verified the knockdown of siSTAT3 by measurement of pY-STAT3 and total 
STAT3 protein levels via western blot that was run in parallel to this assay (Supplemental figure 
S.1). siSTAT3 resulted in increases in both KLF6 and PXN in OVCAR-8CR spheroids, though I 
was more interested in reduced expression. Ultimately, OVCAR-8CR siSTAT3 resulted in the 
significant (P < 0.05) reduction of mRNA expression of STAT3 when compared to OVCAR-8CR 
siControl, but no other STAT3 target genes. siKLF6 resulted in a significant increase in SNAI2 
mRNA expression in both OVCAR-8CS (P < 0.001) and OVCAR-8CR (P < 0.0001) spheroids 
with a 2-fold increase observed in the OVCAR-8CR spheroids over the OVCAR-8CS (P < 
0.0001) (figure 2.7C). siPXN yielded increases in both STAT3 and SNAI2 mRNA gene 
expression in OVCAR-8CS spheroids. siUGCG in OVCAR-8CR spheroids led to increased 
SNAI2 expression. Overall, UGCG appeared to continued to be a promising STAT3 target gene, 
however, when I compared the expression of UGCG in OVCAR-8CR siControl, expression was 
already reduced. I could not state that reduction of expression was due to the knockdown of 
STAT3 and therefore, could not proclaim UGCG to be a STAT3 target from this data.  Of interest 
is the 2-4-fold increase in the mRNA expression of SNAI2 in response to siKLF6 in both 




siRNA of STAT3 target genes yields morphological changes in spheroids 
Knowing that knockdown of STAT3 resulted in modulation of target genes, I wanted to 
assess how these modulations were affecting spheroid growth and whether knockdown of these 
genes was re-sensitizing the OVCAR-8CR spheroids to cisplatin. To accomplish this, I treated 
siRNA transfected spheroids with medium only (control) or 3uM cisplatin. After five days of 
drug treatment, I added NucBlue stain to assess spheroid shape and integrity, and propidium 
iodide (PI) stain to assess dead cells present in and around the spheroids. I expected to see 
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disruption in the integrity of the spheroids that were responding the cisplatin treatment. I took 
images on the EVOS microscope at 20x magnification (figure 2.8).  
OVCAR-8CR spheroids appeared smaller than their OVCAR-8CS counterparts in all 
siRNA conditions. Media only treatment in OVCAR-8CR spheroids showed smaller spheroids 
with disruptions observed in spheroids with knockdowns of siSTAT3 and siSNAI2. Disruption in 
spheroids was observed in all OVCAR-8CR treated with cisplatin, though very little was 
observed in siUGCG spheroids. siUGCG spheroids appeared to have hollow cores in both media 
only and 3uM cisplatin treatment, with the absence of red stained cells. PI stained cells are 
observed around the edge of the spheroids in siUGCG, dismissing any concern that PI was not 
added to these wells. When using EVOS, images are taken at one plane; therefore, PI stained 
cells may be present in the spheroid core at another plane of focus. The most disruption was 
observed in siSTAT3 and siSNAI2 OVCAR-8CR spheroids.  
OVCAR-8CS spheroids treated with media only all showed complete and round 
spheroids with clear blue (live) cells present on the outside of the spheroids, and dense red (dead) 
cells in the centers. Little to no cells were observed outside any of the OVCAR-8CS spheroids 
despite siRNA treatment. OVCAR-8CS spheroids treated with cisplatin appeared to show 
sensitivity to the drug with disrupted outer layers of the spheroids displaying a blurred 
appearance. This was present in all siRNA treatment conditions, though siSTAT3 spheroids 
showed the least amount of disruption in response to drug treatment.  This experiment was 
conducted two times with our in-house adapted OVCAR-8CS and OVCAR-8CR cells, and 
results were reproduced in both experiments. Another experiment like this was executed with the 
cells received from the Chowanadasi et al. research group, which yielded very different results. 
Most notably was the presence of a blebbing of the spheroids of OVCAR-8CR treated with 
42 
 
siUGCG, siPXN and siKLF6, and dosed with 3uM cisplatin. (supplemental figure S.2). Overall, I 
can conclude from this data that there are morphological differences between OVCAR-8CS and 
OVCAR-8CR spheroids grown in 3D. 
 
 
Confocal images show disrupted OVCAR-8CR spheroids 
In an effort to better comprehend how these morphological changes could be re-
sensitizing the spheroids to cisplatin, I decided to stain cells with an additional dye (caspase 3/7 
green) that gives insight into how the cells may be dying (apoptosis). I chose to use confocal 
microscopy to take images on this time because the EVOS only gives us images occurring at one 
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plane at a time, but the confocal gives us the ability to take multiple images throughout the 
entirety of the spheroid and overlay those photos into one image that is representative of what is 
occurring throughout the spheroid. As I did in the previous experiments with the EVOS, I stained 
the spheroids of OVCAR-8CS and OVCAR-8CR cells with a combination of NucBlue and PI. 
This time I also added Caspase 3/7 green dye, which fluoresces in cells that have activated 
caspase 3/7, indicating the cell is undergoing apoptosis. I then compiled the images to gain a 
clear picture of how silencing STAT3 and STAT3 target genes may be re-sensitizing the 
OVCAR-8CR spheroids to cisplatin treatment. Since overexpression of target genes has been 
linked to chemoresistance, and chemoresistance involves evasion of apoptosis, I hypothesized 
that knockdown of my target genes would result in increased apoptosis if re-sensitization to 
cisplatin occurs in OVCAR-8CR cells. UGCG continued to show the most promise with being a 
STAT3 target gene; therefore, I expected to see increased sensitivity to cisplatin in siUGCG 
OVCAR-8CR spheroids (figure 2.9). 
All OVCAR-8CS treated with media only contained round spheroids with smooth 
exteriors and few dead cells located outside of them. The siControl media only treated spheroid 
appeared larger in size when compared to all other siRNA treated media only spheroids, but this 
was because I had zoomed in on that spheroid. Therefore, there is no difference in size between 
the siControl and other siRNA treated OVCAR-8CS spheroids treated with media only.  
OVCAR-8CS spheroids treated with 3uM cisplatin all appeared to have disrupted spheroids, 
with many more cells, stained all colors, present on the outside of the spheroid. This showed that 
the spheroids were sensitive to the cisplatin treatment and were reacting as such by becoming 
disorganized. The siSTAT3 OVCAR-8CS spheroid treated with cisplatin was less disrupted than 
the other siRNA OVCAR-8CS spheroids treated with cisplatin.  
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OVCAR-8CR spheroids appear to be disrupted in all conditions and all siRNA 
treatments. This may indicate a certain amount of toxicity to the transfection reagent. It may also 
be due to the overall differences in gene expression, particularly with EMT genes, between 
OVCAR-8CS and OVCAR-8CR that result in less round and defined spheroids, even without the 
transfection reagent present (figure 2.9). Though not much spheroid disruption was observed in 
either siControl or siSTAT3 OVCAR-8CR spheroids treated with cisplatin, both siUGCG and 
siSNAI2 OVCAR-8CR spheroids treated with media only or cisplatin were disrupted. This 
disruption of the spheroids was not increased in response to cisplatin and so I cannot conclude 
that siUGCG or siSNAI2 re-sensitized OVCAR-8CR spheroids to cisplatin. Overall, the greatest 
responses to cisplatin treatment were observed in OVCAR-8CS spheroids treated with siUGCG 




Knockdown of STAT3 target genes does not re-sensitize OVCAR-8CR spheroids to cisplatin 
With confocal images depicting possible increased sensitivity to cisplatin treatment in 
OVCAR-8CR spheroids with siUGCG and siSNAI2, I wanted to determine if this response was 
measureable in a viability assay. Both OVCAR-8CS and OVCAR-8CR spheroids were 
transfected with siRNA for STAT3 target genes and treated with either media only (control) or 
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3uM cisplatin. Data was normalized to OVCAR-8CS and OVCAR-8CR siControl dosed with 
media only (figure 2.10). 
OVCAR-8CS and OVCAR-8CR spheroids had no significant difference in growth in any 
siRNA transfected cells dosed with media only. OVCAR-8CS spheroids treated with cisplatin 
had significant reduced growth compared to OVCAR-8CS siControl (P < 0.0001) treated with 
media only. This reduced growth was seen in all siRNA transfected OVCAR-8CS spheroids 
treated with cisplatin, with no significant difference in response to cisplatin observed between 
siRNA transfected sensitive spheroids when compared to siControl cisplatin treated sensitive 
spheroids. OVCAR-8CR spheroids maintained their resistance to cisplatin with no significant 
difference in cisplatin response observed in any of the siRNA transfected OVCAR-8CR 
spheroids when compared to the control. Based on our confocal data, I had expected to see re-
sensitization of OVCAR-8CR spheroids to cisplatin in siUGCG and siSNAI2 transfected 





Conclusion for goal 1: 
The first goal of my hypothesis was to identify STAT3 target genes that were enriched in 
the resistant phenotype of the OVCAR-8 spheroids and determine if modulation of these target 
genes resulted in re-sensitization of our OVCAR-8CR to cisplatin treatment. I chose three genes; 
SNAI2, KLF6 and PXN, that were involved in EMT, since increased ability for cancer cells to 
transition between the epithelial and mesenchymal state correlates with chemotherapy resistance. 
I also chose UGCG because it has been shown to be increased in many cancers, including 
ovarian, and because its increased expression correlates with chemotherapy resistance.  
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Although SNAI2 did not re-sensitize OVCAR-8CR spheroids to cisplatin, I did identify a 
novel correlation between siKLF6 and increased mRNA expression in cells grown in 3D, with 
this effect emphasized in the resistant OVCAR-8 spheroids. 
KLF6 initially responded with reduced mRNA expression in response to siSTAT3, and 
increased mRNA expression in 3D growth, making it an attractive STAT3 target gene. 
Ultimately, siKLF6 did not result in re-sensitization of OVCAR-8CR spheroids to cisplatin. 
However, as is mentioned above, I did discover that siKLF6 correlated with dramatic increases in 
SNAI2 in cells grown in 3D, and that this effect is emphasized in the resistant phenotype of our 
OVCAR-8 spheroids.  
PXN had inconsistent results in many of our experiments. I excluded PXN from EVOS 
and confocal experiments due to a lack of evidence of PXN being a STAT3 target gene. 
Therefore, It was no surprise to me that siPXN did not re-sensitize our OVAR-8CR spheroids to 
cisplatin.  
Of the four genes tested, UGCG appeared to be the most likely of my genes tested to be a 
STAT3 target gene. However, it also had reduced expression in OVCAR-8CR spheroids at a 
baseline and did not modulate its expression in response to siSTAT3 afterall. Ultimately, its 
reduced expression did not result in re-sensitization of OVCAR-8CR spheroids to cisplatin.  
These four genes were only a small subset of STAT3 target genes that were found to be 
enriched in the OVCAR-8CR spheroids by Chowanadasi et al. and Dr. Walker; therefore, I 
cannot conclude that STAT3 target genes are not involved in cisplatin resistance, or that 
modulation of STAT3 target genes would not result in re-sensitization of resistant spheroids to 
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cisplatin. I can only conclude that the four genes I chose to look at were not the genes that 
needed to be modulated to achieve cisplatin re-sensitization in OVCAR-8CR spheroids.   
Results for goal two: identification of STAT3 inhibitors that re-sensitize the resistant 
OVCAR-8 spheroids to cisplatin.  
Having found OVCAR-8CR cells have enhanced STAT3 activity, I wanted to determine 
if STAT3 inhibitors were effective at reducing  OVCAR-8CR growth when used alone and/or if 
they could sensitize OVCAR-8CR cells to cisplatin. For this part of my research, I measured the 
effectiveness of STAT3 inhibitors on spheroids utilizing CellTiter-Glo 3D, a luminescent assay 
that measures ATP as an indicator of viability.  
For viability experiments, analyzing results on a bar graph is an accurate way to assess 
the effects that one drug has on a cell line. When treating cells with combinations of drugs, 
effects from the drugs may not be as apparent; therefore, another approach was used called a 
combination index (CI).  A CI is an equation that helps to define synergism between two drug 
combinations. In brief, a synergistic effect is defined as CI < 1, an additive effect as CI = 1, and 
an antagonistic effect at CI > 1 74. For the purposes of my analysis, I accounted for some error on 
either side of the value of 1 and considered the following guidelines for analysis: Synergistic 
effect CI < 0.9, additive effect CI = 0.9-1.1, and antagonistic effect CI > 1.1. Data was input into 
Combosyn software, which generates the CI values, and the results were plotted as an 





Nifuroxazide synergized with cisplatin in OVCAR-8CR spheroids. 
Nifuroxazide (nifu) is an oral antibiotic that is presently used in patients to treat colitis 
and acute and chronic diarrhea in other countries, though it is not currently approved for use in 
the United States. In 2008, nifu was identified to be a STAT3 inhibitor by Nelson et al. I 
therefore wanted to test our paired cell line to determine if nifu alone would reduce spheroid 
growth, or when used in combination with cisplatin, would yield synergistic results in OVCAR-
8CR spheroids. Therefore, I treated spheroids with increasing doses of nifu and cisplatin 
simultaneously and measured the effect using CTG 3D (Figure 2.12).   
Treatment with nifu alone was dose-dependent in OVCAR-8CS spheroids, with 
significant reduction in spheroid growth seen at the highest dose of drug (P < 0.05). Though 
spheroid growth was significantly reduced in OVCAR-8CS spheroids at 5uM treatment when 
compared to control, overall reduction in spheroid growth did not reach 50% and was therefore 
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not potent at the drug doses that were tested. Nifu treatment in OVCAR-8CR spheroids had no 
effect on spheroid growth. The doses of nifu chosen for these experiments were too low to show 
effect in our spheroids when used alone. However, previous data (not shown) testing higher 
concentrations of nifu showed a more potent effect, therefore; I proceeded with combination 
experiments.  The CI for OVCAR-8CS spheroids treated with combinations of nifu and cisplatin 
resulted in three combinations of drugs that had synergistic effects. Several other combinations 
hover around 1, displaying an additive effect. While synergism is observed in OVCAR-8CS 
spheroids, my interest is in re-sensitization of OVCAR-8CR to cisplatin. Nifu shows synergistic 
potential with cisplatin at the highest combination of drug doses in OVCAR-8CR spheroids. 
Additional experiments with higher doses of nifu may result in additional synergism; however, 
higher drug doses of drugs typically mean a higher likelihood of toxicity or side effects in 
clinical settings75. Therefore, while I may be able to achieve synergism with nifu and cisplatin in 
OVCAR-8CR spheroids, the combination needed to have an acceptable effect (50% or more 
reduction in growth) may not be translatable into a clinical setting. With this in mind, I chose to 




Combinations of cisplatin and atovaquone do not yield synergistic responses   
Atovaquone (AQ) is a quinone antimicrobial medication that is FDA approved and 
clinically used in patients to treat or prevent pneumonia caused by a fungal infection caused by 
Pneumocystis jirovecii. In 2016, Xiang et al. identified AQ as a STAT3 inhibitor through a query 
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using the Connectivity Map. Since this is an FDA approved drugs that has been identified as a 
STAT3 inhibitor, we were interested in examining the effects that this drug may have on our 
paired OVCAR-8 cell lines when used in combination with cisplatin. I hypothesized that 
inhibiting STAT3 with AQ in combination with cisplatin would result in synergistic effects in 
OVCAR-8CR spheroids.  
Treatment with AQ alone (figure 2.13A.) had significant effects on spheroid growth in 
both OVCAR-8CS (P < 0.0001 at 10uM, and 15uM) and OVCAR-8CR (P < 0.0001 at 10uM, 
and 15uM). Combinations of cisplatin and AQ (figure 2.13 B-C.), however, did not result in 
synergistic effects in either OVCAR-8CS or OVCAR-8CR spheroids. This was an unexpected 
result as I believed AQ would inhibit STAT3 effectively reducing the resistant effect of 




Combination of cisplatin and atovaquone at low doses has synergistic effects in OVCAR-8CR 
spheroids after staggered addition  
  Since AQ was not synergistic with cisplatin in OVCAR-8CR cells when added 
simultaneously, I then considered what might occur if the addition of AQ occurred 24 hours prior 
to the addition of cisplatin. I theorized that adding AQ prior to cisplatin would allow time for 
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inhibition of STAT3 in the spheroids to occur and this would subsequently increase the 
sensitivity of the spheroids to cisplatin treatment 24 hours later.  
In addition to staggering the treatment of drugs on the spheroids, I also expanded the 
concentrations of cisplatin and AQ tested, giving more combinations to attain synergism with. 
While staggering the addition of AQ and cisplatin did not increase the sensitivity of the 
OVCAR-8CS or OVCAR-8CR spheroids to cisplatin treatment (figure 2.14A.), synergism did 
occur in OVCAR-8CR spheroids at the lowest doses of both cisplatin (1uM) and AQ (5uM) 
tested (figure 2.14C.). In addition to this, several other combinations with lower concentrations 
of both cisplatin and AQ are now on the isobologram for OVCAR-8CR spheroids. While these 
additional points did not fall into the previously outlined range (CI<0.9) to be considered 
synergistic, further expansion of the range at which each of the drugs are tested in the OVCAR-
8CR spheroids may yield more synergistic results. Although synergism was accomplished in 
OVCAR-8CR spheroids, the concentration of drugs used to accomplish synergism was so low 
that the effect was minimal (approximately 24% reduction in growth, figure 14C). It is true that 
low doses of drugs could be less cytotoxic to patients and therefore beneficial to their treatment; 
however, I was looking for at least 50% reduced growth in response to drug treatment. Overall, 
synergistic effects are attainable with combinations of AQ and cisplatin in OVCAR-8CR, 
however the effects on spheroid growth are so minimal, AQ may not be the ideal STAT3 









Statins as potential STAT3 inhibitors 
Several statins were recently identified as potential STAT3 inhibitors in a CMap query 
based on gene expression of siRNA to STAT3, by Brendan Reilly, a PhD candidate in the Sarah 
Walker lab at the University of New Hampshire (unpublished data). Statins are inhibitors of 3-
hydroxy-3-methylglutaryl CoA reductase (HMGCR) and have pleiotropic actions that extend 
beyond reduction of cholesterol76. One of these actions includes anti-inflammatory effects via the 
suppression of monocyte chemo-attractant protein (MCP)-1 expression. IL-6 has previously been 
shown to induce MCP-1, and IL-6 also activates STAT3 through the JAK/STAT pathway76. 
Jougasaki et al. concluded in a study using human aortic endothelial cells (HAECs), that statins 
affect STAT3 by inhibiting IL-6 and its soluble receptor (sIL-6R) from inducing monocyte 
chemotaxis and MCP-1 expression by inhibiting the JAK/STAT signaling pathway76. 
Researchers were also able to show that statins were able to block IL-6/sIL-6R induced 
translocation of STAT3 into the nucleus. Preliminary work completed by Brendan in OVCAR-8 
cells demonstrated reduced cell viability with statin treatment (unpublished data). Therefore, I 
wanted to test their effects in OVCAR-8CR spheroids alone and in combination with cisplatin. I 
tested three different statins; Lovastatin, Simvastatin and Atorvastatin in combination with 
cisplatin to determine if synergistic effects would result.  
Simvastatin and Lovastatin have strong cytotoxic effects in both OVCAR-8CS and OVCAR-8CR 
cells 
Simvastatin and Lovastatin are very similar in structure, and their effects on the spheroids 
are nearly identical. I found that simvastatin and lovastatin had very strong and significant 
cytotoxic effects in both OVCAR-8CS and OVCAR-8CR spheroids, with over 50% (P < 0.0001) 
reduction in cell number observed in both cell lines at the lowest concentration of 5uM (figure 
58 
 
2.15A and 2.16A). Synergistically, there were four combinations of cisplatin and simvastatin 
(figure 2.15C.) and six combinations with lovastatin (figure 2.16C) in OVCAR-8CS spheroids 
that showed synergism with cisplatin, but no synergism was observed in the OVCAR-8CR 
spheroids. While no synergism was observed with either simvastatin or lovastatin when 
combined with cisplatin in OVCAR-8CR spheroids, the effects that these statins had on 
OVCAR-8CR spheroids without combination were apparent. Additional combination studies 
should be investigated with simvastatin and lovastatin where doses of statins are expanded to 







Atorvastatin was synergistic with cisplatin in both OVCAR-8CS and OVCAR-8CR spheroids  
Atorvastatin, the most recent of the three statins tested to be used clinically, alone also 
showed significant cytotoxic effects in both cell lines, but most notably shows 50% death in 
OVCAR-8CR spheroids at 10uM (figure 17A).  Synergistically, OVCAR-8CS spheroids 
responded well to combination treatment, with all concentrations of atorvastatin combined with 
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cisplatin concentrations of 3uM and above showing synergistic results (figure 17C). Two 
combinations of atorvastatin (5uM and 7.5uM) and cisplatin (5uM for both combinations) 
resulted in synergistic results in OVCAR-8CR spheroids as well. In addition, several other 
combinations were close to the range of being considered synergistic. Expanding the range of 
atorvastatin doses combined with cisplatin could result in additional synergistic responses in 




Summary of goal 2: 
The second goal of my hypothesis was to test STAT3 inhibitors recently identified by 
either drug screening or in silico query, in my paired sensitive and resistant OVCAR-8 cells to 
determine if the drugs used alone or in combination with cisplatin would re-sensitize our 
63 
 
resistant spheroids. I tested nifuroxazide, a drug currently used overseas to treat diarrhea 
conditions and found that the doses that were tested may have been too low to see optimal effects 
alone in spheroids. Previous data showed nifu reduced viability dramatically in both OVCAR-
8CS and OVCAR-8CR at 10uM, but dosing spheroids at 7.5uM has no effect on the OVCAR-
8CR spheroids.  Overall, nifu has potential to work in combination with cisplatin, but additional 
concentrations extending between 6uM - 10uM need to be tested.  
Atovaquone is an antimicrobial medication that has been identified as a STAT3 inhibitor 
through CMap query. Atovaquone dosed alone in OVCAR-8CS and OVCAR-8CR is effective at 
reducing growth in both sensitive and resistant spheroids, though no synergy with cisplatin was 
observed. When addition of atovaquone was staggered with cisplatin, we saw synergistic effects 
in OVCAR-8CR spheroids. Additional doses of atovaquone and cisplatin should be tested to 
determine if synergistic effects can be optimized.  
Brendan Reilly recently ran a query in CMap and identified simvastatin, lovastatin and 
atorvastatin as STAT3 inhibitors. Overall, all three statins were effective at reducing spheroid 
growth in both OVCAR-8CS and OVCAR-8CR. Both simvastatin and lovastatin had synergistic 
effects in sensitive spheroids. Expanding the range of doses to include concentrations of both 
simvastatin and lovastatin at lower concentrations in combination with cisplatin may result in 
synergistic effects in OVCAR-8CR spheroids. Atorvastatin had synergistic effects in both 
OVCAR-8CS and OVCAR-8CR spheroids.  
Goal number two of my hypothesis was a success, with all STAT3 inhibitors showing 
effects on spheroid growth either on their own or in combination with cisplatin. Some STAT3 
inhibitors had stronger effects (statins) than others (nifu), but overall, even those with weaker 
64 
 
effects in inhibiting spheroid growth may just need to have their tested concentrations adjusted 
slightly to show greater effects.   
Discussion: 
Considering the experiments performed prior to my arrival, I hypothesized that STAT3 
was promoting cisplatin resistance in ovarian cancer. I identified two goals while investigating 
my hypothesis. The first goal was to investigate potential STAT3 target genes that could be 
contributing to cisplatin resistance. Given that Chowanadasi et al. identified many genes linked 
to EMT expressed in the OVCAR-8CR spheroids, I decided to examine three potential STAT3 
target genes (SNAI2, KLF6 and PXN) that were increased in the resistant OVCAR-8 spheroids 
and involved in EMT.  The fourth potential STAT3 target gene that I chose was UGCG as it had 
previously been linked to chemotherapy resistance in ovarian cancer. The second goal was to 
identify STAT3 inhibitors that re-sensitized resistant cells to cisplatin.  
Early in the research, I discovered that the donated cell lines were not behaving as I had 
anticipated. Loss of resistance to cisplatin in the OVCAR-8CR cell line resulted in a rapid 
depletion of our frozen stocks. Eventually, I chose to take the donated OVCAR-8CS cell line and 
re-sensitize them to cisplatin utilizing the same methods described by Chowanadasi et al.  
Resistance was confirmed in newly generated OVCAR-8CR cell line via repeated comparisons 
of sensitivity to cisplatin to that of the OVCAR-8CS cell line in 3D viability assays measured by 
CellTiter-Glo 3D luminescent ATP assay (figure 2.1). Resistance was considered successful 
when a 2-fold reduction in cellular response to cisplatin at the observable EC-50 for OVCAR-
8CS (3uM) was obtained.  
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With resistance confirmed in our newly adapted paired cell line, I wanted to test the 
successfully adapted resistant cells for increased mesenchymal features. Chowanadasi et al. had 
discovered that genes associated with EMT were enriched in the resistant spheroids. EMT 
confers metastatic properties to cancer cells by enhancing mobility, allowing them to invade to 
other locations in the body and form secondary tumors. I used a mesothelial clearance assay to 
assess the invasiveness of our resistant spheroids and compared it to that of our sensitive 
spheroids. While both OVCAR-8CS and OVCAR-8CR both displayed features of EMT by 
clearing monolayers of mesothelial LP9 cells, OVCAR-8CR cells had more clearance around the 
spheroids when compared to the OVCAR-8CS spheroids, indicating enhanced EMT in OVCAR-
8CR spheroids. It was not surprising to see clearance with the sensitive spheroids, as ovarian 
cancer cells grown in 3D versus 2D have previously been reported to have significantly 
increased mRNA expression levels of cell surface receptors α3/α5/β1 integrins, and matrix 
metalloproteinase–9 (MMP9) protease77. Integrin subunit α3 binds with subunit β1 to form 
integrin α3β1; a receptor for ECM molecules that has been demonstrated to function in cell 
migration and motility78. Increased MMP-9 expression enhances the invasion and metastasis of 
tumor cells79 through proteolytic degradation of ECM of gelatin and type IV, V, XI and XVI 
collagens during tissue remodeling80. 
A limitation to this assay is that I do not quantitatively know the difference in the area 
that was cleared by our spheroids, so observations are qualitative. A future direction would be to 
perform calculations utilizing Celleste software. Another limitation to using the mesothelial 
clearance assay as an indicator of enhanced EMT in our resistant OVCAR-8 spheroids is that I 
do not know exactly what genes are enhanced in OVCAR-8CR compared to OVCAR-8CS 
spheroids. Chowanadasi et al. ran genome wide expression analysis to identify specific genes 
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differentially expressed between their sensitive and resistant OVCAR-8 spheroids. Since I had to 
adapt our own OVCAR-8CS cells to be resistant to cisplatin, and because cell gene expression 
can change in culture over time, a future study would be to run genome wide expression analysis 
on our cells to ensure that genes for EMT are enriched in our OVCAR-8CR. Another variable to 
consider is that I cultured our paired OVCAR-8 cell line in RPMI 1640 because our other 
OVCAR-8 cells that the Walker lab has used over the years grows in RPMI 1640, while the 
Chowanadasi et al. research group grew their cells in DMEM. These distinct media types contain 
supplementation that provide different nutrients to the cells and this could alter their gene 
expression and might explain some of the differences that I found in our OVCAR-8CR cells 
compared to the published data.  
Because I do not have gene expression data specific to our paired OVCAR-8 paired cell 
line, I chose to run additional analysis to confirm differences between our OVCAR-8CS and 
OVCAR-8CR cells. Sarah Walker had previously verified the enrichment of STAT3 genes in the 
OVCAR-8CR spheroids using bioinformatics. Therefore, I chose to run western blots on our 
paired cells to assess differences in pY-STAT3 levels in our OVCAR-8CS and OVCAR-8CR 
cells with the hypothesis that enriched STAT3 genes in OVCAR-8CR spheroids would translate 
to increased pY-STAT3 levels compared to OVCAR-8CS spheroids. I also compared pY-STAT3 
protein levels in our paired cell line grown in 2D versus 3D to determine if there was a change in 
pY-STAT3 in 3D compared to 2D grown cells. 
  pY-STAT3 levels between OVCAR-8CS and OVCAR-8CR cells grown in 2D versus 3D 
yielded inconclusive results. The levels of pY-STAT3 were increased in 3D cells when 
compared to 2D cells for both cell types, but only slight increases were observed in resistant cells 
compared to sensitive cells. These observed changes were not significant when all three results 
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were compared together. Cells grown in 3D allow for differences in cell-cell and cell-ECM 
interactions. These differences have effects on morphology, differentiation, proliferation rates, 
drug metabolism, gene expression and protein synthesis when compared to cells cultured in 
2D81. A recent study looking at triple-negative breast cancer (TNBC) grown in 3D using a 
scaffold showed increases in the gene expression and protein levels EGFR, STAT3, and 
increases in pY-STAT3 levels in their 3D cultures compared to 2D cultures81. These results were 
consistent with another study that showed growth of mammary tumor cells in mice expressed 
higher levels of pY-STAT3 when compared to monolayer cultures82. Therefore, seeing an 
increase in pY-STAT3 levels in our paired OVCAR-8 cells grown in 3D compared to 2D is not 
surprising. Unfortunately, variability between the replicates ultimately resulted in these observed 
differences not being significant. Additional replicates may yield more consistent results and 
should be tested again if future studies are to be done with the paired OVCAR-8 cell line.   
Previous bioinformatics data suggested increases in STAT3 activity in cisplatin resistant 
cells; however, my data did not clearly show increased levels of pY-STAT3 in our OVCAR-8CR 
compared to our OVCAR-8CS cells. I considered that my Western blot data was representative 
of the total amount of pY-STAT3 present in our cells and did not provide information about 
specific location within the cells (eg. Cytoplasm versus nucleus) that pY-STAT3 could be 
occurring. Nuclear/cytoplasmic subcellular fractionation could be carried out in the future to 
determine if differences in pY-STAT3 levels were more striking in the nucleus of OVCAR-8CR 
cells. Regardless of the Western blot results, I knew from prior bioinformatics data, that STAT3 
genes were enriched in OVCAR-8CR. Therefore, I decided to focus on the identification of 
STAT3 target genes that are contributing to the resistant phenotype in our OVCAR-8 spheroids.    
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Chowanadasi et al. found that resistant OVCAR-8 spheroids had increased markers for the 
mesenchymal state with supporting enrichment of EMT genes differentially expressed in the 
OVCAR-8CR compared to the OVCAR-8CS spheroids. EMT-derived tumor cells have acquired 
stem cell properties including evasion of apoptosis and subsequent therapeutic resistance55,81,83. 
Considering the above points, I decided to focus on identifying STAT3 target genes that may be 
involved in EMT and could be contributing to the cisplatin resistance in OVCAR-8CR. SNAI2, 
KLF6, PXN and UGCG were selected; SNAI2, KLF6 and PXN have connections to EMT and 
UGCG was chosen because it has been found to be increased in many cancers, including ovarian 
cancer, and has been linked to chemotherapy resistance.   
I confirmed these genes to be targets of STAT3 by measuring their mRNA expression in 
OVCAR-8 cells transfected with either siControl or siSTAT3. UGCG and KLF6 mRNA 
expression was reduced with siSTAT3 transfection, confirming them as STAT3 target genes. 
Both PXN and SNAI2 had variable mRNA expression; however, because at least one data point 
resulted in reduced expression in response to siSTAT3, I continued research of these genes 
considering their status as STAT3 target genes as inconclusive.  
Increased pY-STAT3 had previously been observed in OVCAR-8 cells grown in 2D 
versus 3D, so I expected to see this increase in activated STAT3 correlate with increased STAT3 
target gene expression in 3D grown OVCAR-8 cells. Because I had confirmed both UGCG and 
KLF6 as STAT3 target genes in a previous experiment, I also expected to see increased mRNA 
expression in UGCG and KLF6 to correlate with increased pY-STAT3.  
Significant increases in mRNA expression for SNAI2 were observed in OVCAR-8CS 3D 
when compared to OVCAR-8CS 2D (P < 0.0001) and OVCAR-8CR 3D when compared to 
OVCAR-8CR 2D (P < 0.0001). There is also a significant increase in SNAI2 mRNA expression 
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in OVCAR-8 CR 3D compared to OVCAR-8CS 3D (P < 0.0001). These results were in line with 
our hypothesis. STAT3 mRNA expression did appear to have increased when comparing 
OVCAR-8CS 2D to OVCAR-8CS 3D, and OVCAR-8CR 2D to OVCAR-8CR 3D, but 
differences were not found to be statistically significant.  
KLF6 did not show significant difference in mRNA expression between OVCAR-8CS 
2D and OVCAR-8CS 3D, or between OVCAR-8CS 3D versus OVCAR-8CR 3D, due to 
variable results producing large error bars. OVCAR-8CR 3D did have a significant increase in 
KLF6 mRNA expression (P < 0.021) when compared to OVCAR-8CR 2D. Therefore, KLF6 is 
increased in OVCAR-8CR spheroids compared to OVCAR-8CR 2D grown cells.  
UGCG mRNA expression was not significantly different between OVCAR-8CS 2D and 
OVCAR-8CS 3D, nor was it significantly different between OVCAR-8CR 2D and OVCAR-8CR 
3D spheroids. There was significant difference in UGCG mRNA gene expression between 
OVCAR-8CS and OVCAR-8CR spheroids; however, the effect observed was the opposite effect 
that was expected. Meaning, OVCAR-8CS 3D had significantly higher UGCG mRNA 
expression (P < 0.001). UGCG is the gene that encodes glucosylceramide synthase (GCS), an 
enzyme that is responsible for the first step in glycosphingolipid biosynthesis; the transfer of a 
glucose residue from UDP-glucose to ceramide, forming glucosylceramide as its product.72. 
Ceramide is a lipid second messenger that induces growth arrest and/or apoptosis in cancer cells. 
Glycosylation of ceramide blocks the anti-tumor effects of ceramide and overexpression of GCS 
has been linked to drug resistance in many cancers72. Therefore, an increase in UGCG mRNA 
expression in OVCAR-8CR 3D spheroids would have been expected. Instead, UGCG had no 
significant change in mRNA expression in either 2D or 3D growth resistant spheroids when 
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compared to the OVCAR-8CS 2D control. PXN did not have any significant change in mRNA 
expression in either 2D versus 3D, or sensitive versus resistant OVCAR-8 cells.  
siRNA experiments with OVCAR-8CS and OVCAR-8CR spheroids resulted in 
successful knockdown of STAT3 target genes (figure 2.7). UGCG continues to have reduced 
mRNA expression in response to siSTAT3 in sensitive spheroids when compared to OVCAR-
8CS siControl, though no significant difference was observed in UGCG mRNA expression in 
OVCAR-8CR siSTAT3 spheroids when compared to OVCAR-8CR siControl. UGCG is also 
reduced in OVCAR-8CR siControl spheroids when compared to OVCAR-8CS siControl. I 
concluded that UGCG is reduced in the resistant OVCAR-8 phenotype.  
From this data, a new and unexpected pattern was revealed. In both sensitive and resistant 
spheroids, siKLF6 coincides with marked increases in SNAI2 mRNA expression. This effect is 
enhanced in the resistant spheroids and is reproducible across experiments. KLF6 is a member of 
a large family of transcriptional regulators, of which KLF6 functions as a tumor suppressor. 
KLF6 is involved in regulating cancer cell proliferation, apoptosis and metastasis, and is reduced 
in many cancers84,85. The N-terminal acidic domain of KLF6 is responsible for recruiting and 
interacting with other transcription factors and corepressors, including KLF486. KLF4 is another 
member of the Krüppel-like family of transcriptional regulators that also has involvement with 
the suppression of EMT and invasion. Specifically, KLF4 is a suppressor of SNAI285. SNAI2 is a 
transcriptional repressor that represses E-cadherin, resulting in increased N-cadherin, a hallmark 
of EMT87. KLF4 and KLF6 both target E-cadherin gene, CDH1. I hypothesize that KLF6 and 
KLF4 co-repress SNAI2 expression, thus explaining the increased expression in SNAI2 in 
response to siKLF6 in PCR experiments with our paired OVCAR-8 cell line.  
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To the best of my knowledge this is a novel concept, one of which will need to be 
investigated further through additional experimentation, involving both KLF6 and KLF4 and 
how they modulate SNAI2 expression. A double knockdown of both KLF6 and KLF4 may result 
in an enhanced response in increased SNAI2 expression. Overexpression of KLF6 may reflect 
increased mRNA expression of KLF4 and decreased mRNA expression of SNAI2. A western blot 
examining SNAI2 protein levels in OVCAR-8 spheroids transfected with either siKLF6, siKLF4 
or double knockdown of both KLF6 and KLF4, may also help to understand if there is co-
repression of SNAI2 occurring with KLF4 and KLF6. If KLF6 and KLF4 are forming a complex 
to repress SNAI2 together, then this should be reflected in the experiments described above as 
modulation of both KLF6 and KLF4 together should result in stronger increases in SNAI2 
expression than if KLF6 and KLF4 were modulated individually.  
Both EVOS and confocal images taken of siRNA transfected cells treated with either 
medium only or 3uM cisplatin yielded similar results. In both cases, all OVCAR-8CR spheroids, 
regardless of drug treatment or siRNA, had spheroids that appeared more disrupted and 
disorganized when compared to OVCAR-8CS spheroids. Of note, OVCAR-8CR tend to grow in 
less organized spheroids in plates, when compared to the round and organized OVCAR-8CS 
spheroids. This difference in morphology is likely due to gene modulation making OVCAR-8CR 
more mesenchymal than OVCAR-8CS. It is also possible that OVCAR-8CR spheroids may be 
sensitive to the transfection reagent, although this is unlikely as we use INTERFERin siRNA 
transfection reagent, which is less toxic to cells than other transfection reagents.  
Caspase 3/7 green was used in addition to nucblue/PI staining for the images taken on the 
confocal microscope (figure 2.9). Caspase green stains caspase 3, a protein active when cells 
undergo apoptosis, and allows us to better understand how cells are dying in the spheroids. Many 
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of the centers of spheroids fluoresced green, indicating apoptosis was occurring. The centers of 
spheroids receive less nutrients from the medium they are grown in and therefore tend to contain 
quiescent and hypoxic cell populations.88 While mild hypoxia can be protective in many cancer 
cell lines, prolonged and severe hypoxia may initiate apoptosis or necrosis.89 This may explain 
why there is presence of cells stained by the Caspase 3/7 Green in the core of the OVCAR-8CS 
spheroids, indicating cells that are undergoing apoptosis  
OVCAR-8CR spheroids are less organized than the OVCAR-8CS spheroids as is seen by the 
dispersion of cells outside of the spheroids of the OVCAR-8CR in both medium only and 
cisplatin treatment. This may be due to the differences in gene expression between the sensitive 
and resistant spheroids. I know that the OVCAR-8CR spheroids have increased expression of 
EMT genes from Chowanadasi et al.; therefore, these cells have epithelial-mesenchymal 
plasticity (EMP) compared to OVCAR-8CS. The ability for these cells to transition between 
EMT and MET may affect the appearance of the spheroids and contribute to dispersion of cells 
outside of the spheroid. This effect is emphasized in siUGCG and siSNAI2 OVCAR-8CR 
spheroids treated with either medium only or cisplatin where cells of all colors exist around the 
spheroid. Overall, knockdown of STAT3 target genes of interest did not re-sensitize OVCAR-
8CR spheroids to cisplatin.  
Experiments investigating the first goal of my thesis of identifying STAT3 target genes 
that could be responsible for cisplatin resistance in OVCAR-8CR were unsuccessful. PXN 
expression was not modulated in any discernable pattern in response to siSTAT3. Initial 
experiments with KLF6 were promising as decreased mRNA expression of KLF6 correlated with 
siSTAT3; however, siSTAT3 in OVCAR-8CR spheroids had opposite effects, resulting in 
increased KLF6 mRNA expression. SNAI2 was inconsistent in its response to siSTAT3. 
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Experiments in mRNA expression levels between 2D and 3D growth in OVCAR-8CS and 
OVCAR-8CR cells concluded that SNAI2 mRNA expression is correlated more with 3D growth 
than resistance. UGCG was the most consistent with its results correlating with STAT3 across 
our experiments; however, siRNA experiments with STAT3 target genes revealed decreased 
UGCG levels in OVCAR-8CR siControl spheroids. Finally, knockdown of STAT3 target genes 
did not result in re-sensitization of OVCAR-8CR spheroids to cisplatin treatment. Although 
PXN, KLF6, SNAI2 and UGCG may not be the STAT3 target genes responsible for increased 
resistance in OVCAR-8CR cells, other STAT3 target genes should be investigated further. 
Perhaps further investigation into anti-apoptotic genes (BCL-2 and BCL-xL) would yield a more 
promising result.   
The second goal of identifying STAT3 inhibitors that re-sensitized OVCAR-8CR 
spheroids to cisplatin was approached through combination viability assays.  The doses of 
nifuroxazide chosen for these experiments were too low to show synergistic effect in spheroids 
when used alone; however, previous data (not shown) testing higher concentrations of nifu 
showed a more potent effect. When dosed with nifu at 10uM, both OVCAR-8CS and OVCAR-
8CR were greatly reduced, with OVCAR-8CS below 0.2 and OVCAR-8CR at approximately 0.2 
relative growth when compared to control. Dosing at 7.5uM; however, had no effect on 
OVCAR-8CR spheroids, but OVCAR-8CS spheroids had 50% reduction in growth. Additional 
higher concentrations of nifuroxazide could be investigated to determine if synergistic effects are 
attainable with cisplatin, but ideally synergistic drug combinations would be found in low doses 
of drugs being studied. Low drug doses are ideal for translation of the combination therapy into 
clinical use as lower drug dosing results in lower side effects75. Perhaps staggering the addition 
of nifuroxazide 24 hours ahead of addition of cisplatin to cells would result in synergistic 
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results? This approached showed promise with atovaquone, and should be tested with 
nifuroxazide.  
Initial viability experiments with atovaquone and cisplatin did not show synergism; 
however, atovaquone reduced OVCAR-8CR spheroid viability by 50% on its own. It was later 
determined through experiments performed by my peers, that atovaquone was precipitating out 
of solution at concentrations of 15uM and above. Precipitation was observed during initial drug 
dilution, and in EVOS images that revealed large crystalline structures that were disrupting the 
spheroids. Because of this, I decided to keep atovaquone concentrations at 12.5uM and below for 
a follow-up experiment where I added atovaquone to OVCAR-8CS and OVCAR-8CR spheroids 
24 hours prior to cisplatin to see if atovaquone would inhibit STAT3 and re-sensitize OVCAR-
8CR spheroids to the latter addition of cisplatin.  
For the experiments where addition of atovaquone and cisplatin were staggered to 
potentially enhance synergism, we broadened our range of both atovaquone and cisplatin to 
include additional doses at lower concentrations. Increasing the range of drug concentrations 
tested for both drugs resulted in synergism in OVCAR-8CR spheroids at the lowest drug 
concentrations for both atovaquone (5uM) and cisplatin (1uM). Unfortunately, the combination 
of atovaquone at 5uM and cisplatin at 1uM did not result in a significant reduction in viability of 
OVCAR-8CR spheroids. Where synergism is occurring in lower concentrations of the drugs, it is 
unlikely that extending these drug combinations to include lower concentrations of atovaquone 
would result in increased reduction of growth in the resistant spheroids.  
Simvastatin, lovastatin and atorvastatin were all recently identified by Brendan Reilly 
from Dr. Sarah Walker’s lab, as STAT3 inhibitors. Simvastatin and lovastatin are structurally 
alike and had similar results in combination with cisplatin. Both showed synergism in OVCAR-
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8CS spheroids but not in OVCAR-8CR spheroids. Though they do not re-sensitize our resistant 
OVCAR-8 spheroids to cisplatin, they are very effective on their own with 50% reduction in 
OVCAR-8CR viability observed at 5uM. Being that these statins are potent at lower 
concentrations, it would be worth testing lower concentrations of simvastatin and lovastatin in 
combination with cisplatin to determine if synergism is attainable. Staggering addition by dosing 
cells with simvastatin or lovastatin 24 hours before cisplatin may also result in synergistic results 
and shouldbe tested. Regardless of synergism with cisplatin, further studies of these statins and 
their ability to reduce resistant ovarian cancer 3D cell growth is warranted.  
Atorvastatin had 50% reduction in growth in OVCAR-8CR spheroids at 10uM when 
tested alone. Two combinations of atorvastatin and cisplatin were synergistic in OVCAR-8CR. 
These two combinations also resulted in 50% or greater reduction in OVCAR-8CR spheroid 
growth. Lower doses of atorvastatin should be tested in combination with cisplatin to determine 
if this synergistic effect can be enhanced. Staggering the addition of atorvastatin and cisplatin by 
24 hours may also yield synergistic results. Atorvastatin has potential at treating 
chemotherapeutic resistant ovarian cancer and should be investigated further.  
Conclusion: 
Both Chowanadasi et al. and Dr. Sarah Walker discovered that STAT3 genes are 
enriched in OVCAR-8CR spheroids when compared to OVCAR-8CS spheroids. Brittnee Wirth 
further confirmed a correlation between STAT3 and resistance when overexpression of STAT3 in 
OVCAR-8CS resulted in cisplatin resistance. From this data I hypothesized that increased 
STAT3 activity was causing chemotherapy resistance in ovarian cancer and chose to look at 
STAT3 target genes that were enriched in the OVCAR-8CR cells in an effort to modulate 
expression and re-sensitize OVCAR-8CR to cisplatin. I also chose to test STAT3 inhibitors in 
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combination with cisplatin with a goal of identifying one that would synergistically re-sensitize 
OVCAR-8CR spheroids to cisplatin.  
I identified PXN, KLF6 and SNAI2 as STAT3 target genes that were involved with EMT 
and chose to research them further because of the role that EMT has with increased therapeutic 
resistance. UGCG was also identified as a STAT3 target gene and was chosen for additional 
research for its role in inhibition of apoptosis and subsequent chemotherapy resistance, through 
glycosylation of tumor suppressor ceramide. The STAT3 target genes I chose did not link 
STAT3 to cisplatin resistance. Although these genes did not re-sensitize OVCAR-8CR spheroids 
to cisplatin and therefore did not support my hypothesis; a potentially novel link between KLF6, 
KLF4 and SNAI2 may have been identified through my research. 
I chose the STAT3 inhibitors nifuroxazide, atovaquone and recently identified 
simvastatin, lovastatin and atorvastatin to test in combination with cisplatin to re-sensitize 
resistant OVCAR-8 spheroids, for the second goal of testing my hypothesis. Atorvastatin had the 
most promising synergistic effects in OVCAR-8CR spheroids, but additional doses of 
atorvastatin and cisplatin should be tested to see if this effect can be enhanced further. The 
synergistic results from the STAT3 inhibitor atorvastatin supported my hypothesis that STAT3 
was causing resistance in our OVCAR-8CR spheroids. Though the gene or genes responsible for 
cisplatin resistance in advanced ovarian cancer is still unknown, my research has identified 
potential STAT3 inhibitors that could be effective at treating ovarian tumors that have become 
resistant to chemotherapy, either on their own or in combination with cisplatin. Further research 
is needed to investigate the potential of simvastatin, lovastatin and atorvastatin, but preliminary 
viability assay has shown potent responses in my cisplatin resistant HGSOC cell model.  
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